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THE PhD PROJECT: AIM AND OUTLINE  
 
Direct administration of drugs to the lungs has been used for millennia as a 
major treatment for a number of diseases. Origin of the inhalation therapies 
can be found 2000 B.C in India, where people were used to smoke Atropa 
belladonna leaves to suppress cough.  
 
 
Evidence of the use of medication for inhalation dating back to 1886.  
 
In 1986, researchers at Genentech Inc. (San Francisco, USA) discovered that 
the hormone of the human growth was naturally absorbed into systemic 
circulation of rats after its instillation into their lungs. Thus, the development 
of new inhalation medicines for both local and systemic administration raised 
a growing interest of academic and industrial researchers in the last 30 years. 
The first breakthrough for the treatment of a chronic systemic disease via 
inhalation was the inhaled insulin (Exubera®, Pfizer, New York, USA), 
available in USA from 2006 to 2007, then withdrawn from the market for 
economic reasons. The idea that serious diseases, such as diabetes, could be 
treated by pulmonary administration was going to be abandoned, until FDA 
(2014) decided to approve a new form of inhalable insulin, Afrezza® (Sanofi 
and MannKind, USA), obtained by a synergy of an innovative inhaler device 
Dreamboat
TM
 and the Technosphere® technology. 




Although pulmonary route is currently being exploited in ways never 
imagined before, local pulmonary drug delivery remains the preferred route 
for the administration of drugs to treat lung diseases, including tuberculosis, 
asthma, COPD and Cystic Fibrosis (CF). 
A drug administered by the pulmonary route directly targets the airways with 
minimized systemic side effects, rapid pharmacologic response and reduction 
in the required dose. Traditional inhalers, namely MDIs (Metered Dose 
Inhalers), incorporate a propellant into the formulation, which provides the 
energy for aerosolization upon actuation. The MDIs major drawback is the 
need that patient must well coordinate both inhalation and actuation. Solvent- 
and propellant-free DPIs (dry powder inhaler) are breath-actuated, hence 
removing the coordination requirement above. Moreover, it has to be noted 
that an inhaler must 1) allow powder dispersion upon inhalation at reasonable 
flow rates, 2) have flow-rate-independent performances. As the dry powder 
formulation and the device have to be intrinsically linked to obtain a unique 
inhalation product, DPI is considered one of the most complex pharmaceutical 
product.  
It is well known that a good deposition into the lung requires particles with an 
aerodynamic diameter in the range 1 to 5 µm. Different technologies are 
available to successfully produce inhalation medicines with desirable 
characteristic, including particle shape, size, adhesiveness, morphology and 
roughness. However, no standardized methods and correlated regulatory 
requirements are available to predict the fate of particles after the lung 
deposition. Hence, the old concept of pulmonary drug delivery, which states 
that “efficient aerosol generation and particle deposition in the lung are the 
main and only challenges for effective inhalation therapy”, is no longer valid 
(Ruge et al. 2013). 
The lack of standardized methods for the dissolution testing hinders a 
complete knowledge of the processes occurring after particles deposition in 
 Aim of the project 
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the respiratory tract. The Biopharmaceutics Classification System (BCS) 
established by Amidon and co-workers (Amidon et al. 1995) for the 
gastrointestinal absorption, predicting the in vivo pharmacokinetics of the 
drugs, is not transferable to pulmonary case. Lung administration requires an 
ad hoc study taking into account the lung specific biology (metabolism, 
clearance, mucus and surfactant) as well as the characteristics of formulation 
and solubility of drugs, as those parameters affect the pulmonary 
bioavailability. 
Moreover, in some pathologies, such as cystic fibrosis (CF), the presence of a 
thick viscid mucus may reduce the efficacy of the inhalation therapy. Thus, the 
study of drug–mucus interaction is a crucial step in CF to check the ability of 
the drug to penetrate and distribute through airways surface fluids. 
In the last decade, the Research Group in Pharmaceutical Technology of the 
University of Salerno has been involved in developing new dry powders for 
inhalation. Currently, the Group has active projects in this area addressing 
topics such as development of DPIs containing antibiotic, anti-inflammatory 
and antioxidant drugs. In this frame, the aim of the present PhD project was to 
design inhalable powder-based formulations that could improve the treatment 
of pulmonary diseases, mainly cystic fibrosis. Then, the first step of the project 
was to formulate in a respirable form the Ketoprofene lysine salt, a 
nonsteroidal anti-inflammatory drug (NSAID) using the well-known Mini 
Spray Drying and the innovative Nano Spray Drying technology, and to 
evaluate limits and strengths of these different techniques. Moreover, the 
research focused on in vitro assays to evaluate the aerodynamic behavior 
through the respiratory system of the produced powder, using the monodose 
DPI as device for the powder aerosolization. 
In the second part of the project, an in vitro method based on Franz-type 
diffusion equipment was proposed to predict the fate of drugs after deposition 
and to study drug dissolution/permeation processes. Moreover, to better mimic 




the pulmonary environment, permeation properties of the drug were evaluated 
through artificial and/or native CF mucus layer. To this purpose, a mucus 
model was prepared taking in account physico-chemical composition and 
rheological behavior of CF bronchial sputum. 
The final part of the project was performed at the Woolcock Institute of 
Medical Research in Sydney, under the supervision of Professors Daniela 
Traini and Paul M. Young. The research was aimed to study permeation 
processes of several antibiotics across Calu-3 cell line to obtain key 
information for the future formulation of inhaled products. 
Specific objectives of the project were: 
 i) design and development of Dry Powder Inhalers containing Ketoprofene 
lysine salt micronized powders by Mini and Nano spray drying production; 
ii) optimization of the aerodynamic characteristics of the powders, through 
the use of selected and safe excipients (amino acids) able to improve the 
powder flow properties and dispersion which, in turn, may increase lung 
deposition of the drugs (SECTION A). 
 i) optimization and development of a model of Cystic Fibrosis artificial 
mucus for the permeation experiments; ii) rheological characterization of 
Cystic Fibrosis mucus patients; iii) permeation studies of developed 
formulations through both artificial and native CF mucus (SECTION B). 
 investigation of the correlation between physico-chemical properties of 
different antibiotics, such as molecular weight, solubility, LogP and 





















































































1.1 Pulmonary drug delivery: general background 
 
Drug delivery to the lung is undoubtedly an effective strategy for the treatment 
of chronic respiratory diseases, but it is gaining substantial interest as an 
alternative route for the administration of systemically acting drugs that are 
poorly absorbed from the gastrointestinal tract or are metabolized liked 
polypeptides, proteins, genes or vaccines (Stegemann et al. 2013).  
Concerning local therapy, respiratory diseases such as asthma, cystic fibrosis, 
chronic obstructive pulmonary disease, take advantages from direct 
administration of drugs to the lung in form of micronized droplets or solid 
particles. The benefits of local lung delivery includes rapid clinical response 
and minimized systemic toxicity due to reduction of overall required doses. 
On the other hand, concerning systemic therapy, the lungs are an efficient way 
for drugs to reach the bloodstream due to the large surface area available for 
absorption (~100 m
2
), the very thin absorption membrane (0.1–0.2 µm) and 
the elevated blood flow (5 l/min), which rapidly distributes molecules 
throughout the body. Moreover, the lungs exhibit relatively low local 
metabolic activity, and unlike the oral route, pulmonary inhalation is not 
subject to first pass metabolism (Adjei et al. 1994). However, pulmonary 
administration presents the difficulty of achieving efficient and regular 
deposition of the drug in the bronchial or alveolar regions of the respiratory 
tree, a filter aerodynamically efficient that hinders the deposition of the drug.  
Moreover, the deposition and the bioavailability of the Active Pharmaceutical 
Ingredients (API), depend on both the formulation and the device that ensures 
the delivery of the correct dose of drug. Therefore the inhaled product has to 
be considered one of the more complex of all the pharmaceutical forms, 
because it is formed by an active and a special device which must be 






1.2 Anatomy and physiology of the respiratory system 
 
To fully understand the issues related to the administration of drugs via 
inhalation, it is important to consider the anatomic and physiologic aspects of 
the respiratory system. The latter is formed by the nasal cavity, pharynx, 
larynx, trachea, bronchi and lungs. The upper airway include the nasal cavity, 
pharynx and associated structures, while the lower airways consist of the 
larynx, trachea, bronchi and lungs. The human respiratory tract presents itself 
as a branched system of channels for the air with more than 23 bifurcations 
from the mouth to the alveoli, resembling an inverted tree with a single trunk. 
The most widely used morphological model to describe the lung structures 
was initially given by Weibel who divided the respiratory tract into four 
regions (Weibel 1965) (Fig. 1). The upper respiratory tract is the first region 
and includes the nose, mouth and pharynx. Its main feature is the heating and 
air humidification.  
 
 
Figure 1: Airways generations. 
 
The second region is the conduction zone which consists of the first 16 
generations of branches. The transition zone is the third region that goes from 




which occur limited exchange of gas. The fourth area includes respiratory 
generations 20-21-22 and 23 and ends in the alveoli. 
 
1.2.1 Cell types lining the pulmonary airways 
 
The entire respiratory tract is lined with a continuous sheet of epithelial cells 
which vary in type and function throughout the tracheobronchial tree (Fig. 2) 
(Gail et al. 1983, Jeffery 1983). 
 
Figure 2: Comparison of the lung epithelium at different sites within the lungs. 
 
The respiratory epithelium lining the upper airways is classified as a ciliated 
pseudostratified columnar epithelium. 
The most prominent epithelial cells are the ciliated columnar cells, that line 
the airways from the trachea through the terminal respiratory bronchioles. 
From their apical surface protrude the cilia, that provide a sweeping motion of 
the mucus coat and play a crucial role in removing of small inhaled particles 
from the lungs. 
Goblet cells, so named because they are shaped like a wine goblet, are 
columnar epithelial cells that contain membrane-bound mucous granules and 





material and pathogens moving through the airway. They are present 
throughout the larger airways down to the small bronchi but are not found in 
bronchioles (Verdugo 1990). 
Clara cells are not ciliated cells that have a spheric-shaped apical surface 
founded among ciliated cells. They are secretory cells and prevent the luminal 
adhesion, particularly during expiration by secretion of a surface-active agent 
(a lipoprotein) (Evans et al. 1986). 
The alveolar epithelium is composed of a thin, non-ciliated, non-mucus 
covered cell layer consisting mainly of type I pneumocytes and type II 
pneumocytes (Gail et al. 1983). The first ones cover about the 95% of the 
alveolar surface area and are squamous. It is through type I cells that gases 
diffuse to allow oxygen and carbon dioxide exchange with pulmonary 
capillary blood. Type II cells have a more cuboidal shape and cover the 
remaining 5% of the alveolar surface. The main functions of type II cells are to 
produce pulmonary surfactant and to differentiate into type I cells after 
epithelial barrier injuries (Fehrenbach 2001). 
Drug uptake from the lung will be affected in rate and extent both by 
formulation characteristics and drug physicochemical properties (partition 
coefficient, solubility, molecular weight). In particular, macromolecules are 
absorbed to a degree that is inversely proportional to their molecular weight. 
At this level, the mucus (1-10 µm thick) and the surfactant act as physical 
barriers to drug absorption, in particular in the case of peptides and protein. In 
addition, pulmonary enzymes deleterious for peptidic drugs are present, even 
though at smaller concentrations than in the GI tract. Finally, the alveoli are 
populated by freely roaming macrophages acting as scavengers for inhaled 






1.3 Factors affecting aerosol deposition 
 
The inhalation product is probably the most complex of all the pharmaceutical 
forms: while in an oral formulation, the bioavailability depends on aspects 
such as solubility, dissolution rate, diffusion and stability, in the case of a 
pulmonary formulation, the bioavailability also requires that the dose of drug 
is deposited in the lower respiratory tract (Brain et al. 1976). A failure in 
deposition may result in a failure of efficacy. Since particles geometry appears 
so relevant to the behavior of the inhaled particles, determining the 
respirability of an inhalation product, the concept of aerodynamic diameter 
has been introduced to measure the size of particles to be inhaled. The 
aerodynamic behavior of particles depends on the so-called “aerodynamic 
diameter” (Dae), a spherical equivalent diameter that derives from the 
equivalence between the inhaled particle and a sphere of unit density (ρ0) 





    (1) 
 
where Dv is the volume-equivalent diameter, ρ is the particle density and χ is 
the dynamic shape factor (Depreter et al. 2013). The dynamic shape factor is a 
correction factor that takes into account the non-sphericity of the particle: it is 
equal to 1 for a sphere and greater than 1 for irregular particles. 
Hence, particle geometry, density and volume diameter are the main 
characteristics to customize since they affect inhalation performance (Buttini 
et al. 2012). It is generally accepted that particles with an aerodynamic 
diameter of 1-5 µm (referred to as the “respirable range”) tend to deposit in the 
lungs, while particles larger than 5 µm are trapped in the upper respiratory 





1.4 Mechanisms of particles deposition in the lungs 
 
Aerosol particles entering the lungs may be deposited in the airways by 
several mechanisms. These include impaction, sedimentation, diffusion, 
interception and electrostatic precipitation (Gonda 1988). Understanding the 
differences in these deposition mechanisms and how they may affect the 
performance of formulations for inhalation is required to efficiently delivery 
drugs to the airways of the lungs. 
 
1.4.1 Inertial Impaction 
 
Inertial impaction is the dominant deposition mechanism for particles larger 
than 1 µm in the upper tracheobronchial regions. A particle with large 
momentum (large size or velocity or both) may be unable to change direction 
with the inspired air as it passes the bifurcations of the airways, and instead it 
will collide with the airway walls. Because impaction depends on the 
momentum of the particle, large or dense particles moving at a high velocity 




Gravitational sedimentation is an important mechanism for deposition of 
particles bigger than 0.5 µm and smaller than 5 µm in the small conducting 
airways. It is favored by slow, deep breathing and apnea. Deposition due to 
gravity increases with enlarging particle size and longer residence times but 









Submicron-sized particles acquire a random motion caused by the impact of 
surrounding air molecules. This Brownian motion may then result in particle 
deposition by diffusion, especially in small airways and alveoli, where bulk 
airflow is very low. Therefore, to reach the lower respiratory tract and 
optimize pulmonary drug deposition, aerosols need to have aerodynamic 
diameters between 1 and 5µm (Zanen et al. 1996). In other words, particles 
larger than 5 µm usually deposit in the oropharynx from which they are easily 
cleared. In contrast, particles smaller than 1 µm may not deposit at all because 




Interception is likely to be the most effective deposition mechanism for 
aggregates and fibers. For such particles, deposition may occur when a particle 
contacts an airway wall, even though its center of mass might remain on a 
fluid streamline (Yeh et al. 1976, Gerrity et al. 1983, Darquenne et al. 2004).  
 
1.4.5 Electrostatic deposition 
 
Electrostatic charges enhance deposition by increasing attractive forces to 
airway surfaces, in particular for fresh generated particles. 
1.5 Devices for inhalation products 
 
According to the European Pharmacopoeia three devices can be used to 
release a drug in the form of aerosols in the lungs: 
- Nebulizers; 





- Dry powder inhalers (Dry Powder Inhaler, DPI). 
This classification is based on the physical states of dispersed-phase and 
continuous medium, and within each class further differentiation is based on 
metering, means of dispersion, or design. 
Nebulizer has been the first device developed for inhalation therapy market. It 
consists of a reservoir containing a solution or suspension of drug connected to 
a facemask or mouthpiece through which the patient breathes normally. The 
drug-containing liquid is aerosolized by ultrasound or application of 
compressed gas. Today nebulizers have become niche products, because of its 
numerous disadvantages including delivery inefficiency, drug wastage, non-
portability, poor reproducibility, great variability and high cost. Moreover, 
aerosol administration via nebulization is time consuming; approximately 30 
min if set-up, drug administration and cleaning are taken into account. Thus, 
further improvement in aerosol delivery systems with greater efficiency and 
portability and shorter administration time could improve patient quality of 
life and compliance. 
In a pressurised metered dose inhaler (pMDI) the drug is dissolved or 
suspended with a propellant in a pressurized dispenser and is aerosolized 
through an atomization nozzle using a metering valve and an actuator 
(Newman 2005).  
Unfortunately, there are several drawbacks associated with pMDIs. The 
chlorofluorocarbon (CFC) compounds formerly used as the propellant have 
recently been phased out as they were implicated in atmospheric ozone 
depletion. CFC were substituted by hydrofluoroalkanes (HFA), given its safety 
profile (Emmen et al. 2000). One of the principal limitations of pMDIs is the 
requirement that the patient must co-ordinate device actuation with their 
inhalation because of the high exit velocity of the aerosol cloud (Pauwels et al. 
1997). Breath-actuated pMDIs and the use of spacer devices helped in 




The possibility to deliver high doses, the greater stability compared to liquid 
formulations and the problems releated to the use of pMDI have recently 
moved the research in the direction of formulating dry powder inhalers (DPIs) 
(Islam et al. 2008, Son et al. 2008). These devices are typically as portable and 
easy to use as pMDIs but since the aerosol is typically produced by the 
inspiration of the patient, there is no coordination issue between device 
actuation and patient inspiration (Cochrane et al. 2000, Epstein et al. 2001). 
Furthermore, DPIs do not require the use of propellants, removing the cost 
associated with the generation, transport, and storage of the propellant and 
their unwanted environmental impact. Moreover, DPIs are preferred for their 
stability and processing since they are typically formulated as one phase, 
solid-particle blends. 
Currently there are essentially four types of DPIs (Islam et al. 2012): 
 Single-unit dose (capsule) (Fig. 3); This inhaler requires the patient to 
load a single hard gelatin capsule containing the powder formulation 
into the device before each use. This is a very common type of DPI 
device currently available on market. 
 Single-unit dose (disposable); It is a device containing a pre-metered 
amount of a single dose that is discarded after use.  
 Multi-unit dose (pre-metered unit replaceable set) (Fig. 4); Multi-unit 
devices deliver individual doses from pre-metered replaceable blisters, 
disks, dimples or tubes. 
 Multiple dose (reservoir); Multiple dose reservoir inhalers contain a 
bulk amount of drug powder in the device with a built in mechanism to 
meter a single dose from the bulk and individual doses are delivered 






       
 
 
1.6 Excipients approved for use in DPIs 
 
Owing to their small size, microparticles are extremely adhesive and cohesive 
resulting in low dispersibility and, consequently, poor flow properties (Chew 
et al. 2002). One way to improve the aerodynamic performance of an inhaled 
product is through the addition of excipients (Shoyele et al. 2011). Many 
compounds that could enhance drug delivery outcomes also have the potential 
to irritate or injure the lungs, so when formulating an inhalation dosage form 
the structural and functional integrity of respiratory epithelium must be 
respected (Telko et al. 2005). The current excipients approved by the Food 
and Drug Administration (FDA) for respiratory drug delivery are very limited 
in number and not accepted world-wide. The array of potential excipients is 
limited to compounds that are biocompatible to the lung and can easily be 
metabolized or cleared, like sugars (lactose, mannitol and glucose) and 
hydrophobic additives (magnesium stearate, 1,2-Distearoyl-sn-glycero-3-
phosphocholine). In the last few years, amino acids (AAs) have been tested as 
alternative excipients due to their ability to decrease hygroscopicity and 
improve surface activity and charge density of particles. Different studies have 
demonstrated that co-spray-drying of few selected amino acids with active 
Figure 3: Tobi Podhaler®, single-
unit dose (capsule) 
Figure 4: Diskus®, Multi-unit dose 




compounds provides enhanced aerodynamic properties of the final dry 
powders (Li et al. 2005, Seville et al. 2007, Aquino et al. 2012). 
Moreover, as amino acids are endogenous substances, they might not present a 
risk of toxicity to the lungs (Pilcer et al. 2010). Different amino acids such as 
arginine, aspartic acid, phenylalanine, threonine and leucine have been tested 
in dry powder formulations as enhancer of aerodynamic properties, the most 
noteworthy effects have been observed with leucine (Aquino et al. 2012, 
Depreter et al. 2013). For example, selection of appropriate solvent systems 
and leucine concentration has allowed to produce highly respirable β-
oestradiol spray-dried powders (Rabbani et al. 2005). The influence of leucine 
amount on powder dispersibility and manufacturability has been reported. A 
10–20% (w/w) of leucine in spray-dried ethanol or water solutions gives good 
aerosolization characteristics to peptides or sodium cromoglycate (Chew et al. 
2002, Rabbani et al. 2005). It is suggested that addition of leucine results in 
less cohesive particles and in a decrease of particle size due to the surfactant 
behavior of leucine, reducing the size of droplets produced during atomization 
(Vehring 2008). Spray-dried isoleucine has also been shown to improve the 
aerosol performance and stability of various formulations. Trileucine has also 
been proven to be an efficient surface active agent able to produce corrugated 
particles of low cohesivity (Lechuga-Ballesteros et al. 2008). In this case, the 
stabilization mechanism seems to be different: as a result of its surface 
activity, trileucine molecules can orient the hydrophobic groups towards the 
air at the air/liquid interface during the drying process, providing a 
hydrophobic surface to the dry particle, thereby contributing to the observed 








1.7 Particles engineering 
 
Particles engineering approaches range from traditional micronization methods 
to novel and sophisticated Micro- or Nano-encapsulation techniques. 
As well known, traditional methods used to produce micrometric particles, 
such as crushing/milling and crystallization/precipitation, lead to products with 
a poor control of particle size, shape and morphology (Chow et al. 2007, Hu et 
al. 2008, Joshi 2011). Alternatively, super critical fluid drying (SCF) and 
spray drying are mentioned frequently in the literature (Reverchon 2002, 
Mosen et al. 2004, Pasquali et al. 2008) which allow to control, not only the 
size distribution, but also to a certain extent the particle shape and (surface) 
morphology (Hoppentocht et al. 2014).  
Actually, spray drying is the most commonly technology used to generate 
inhalable engineered particles (Parlati et al. 2009, Wu et al. 2013). 
Mini and Nano Spray drying (SD) technologies represent well know and new 
interesting route for particle formation, avoiding most of the drawbacks of the 
traditional processes.  
Here are reported both the classic (mini SD) and innovative (nano SD) 
techniques selected to produce respirable dry powders. 
 
1.7.1 Mini Spray Dryer 
 
The most known instrument which uses the spray drying technology the Mini 






Figure 5: Mini Spray Dryer 
 
Three basic operations can be recognized in the process of spray drying: 
atomization, drying and separation. The product to be dried, prepared in liquid 
form, is sucked from a solution and is transported to a pneumatic atomizing 
nozzle with a diameter of 0.5 or 0.7 mm by means of a peristaltic pump. 
Subsequently, the feed solution is nebulized by atomizers in small droplets in a 
drying chamber in which hot air circulates. The thermal contact between the 
spray droplets and the hot air causes the rapid evaporation of the solvent with 
the formation of solid particles dried or partially wet, generally spherical 
shape, which are then separated from the gas through a cyclone, an 
electrostatic precipitator or a filter (Pilcer et al. 2010). 
The chemical composition of the solid particulates depends on the content 
within the feed solution, whereas particle size and morphology are strongly 
dependent on process parameters such as liquid and gas feed rate, inlet 
temperature, gas pressure and aspiration (Vehring 2008, Maas et al. 2011).  
 
1.7.2 Nano spray dryer 
 
The Nano Spray Dryer (Fig. 6) is a novel spray dryer which offers an 





or organic solutions, suspensions and emulsions. The technological novelty of 
this patented spray dryer lies in the gentle laminar drying flow, the vibrating 
mesh spray technology and the highly-efficient electrostatic particle collector 
(Li et al. 2010, Arpagaus 2012). 
 
 
Figure 6: Nano Spray Dryer 
 
The head is equipped with a piezoelectric crystal consisting of a thin 
membrane of stainless steel with an array of tiny micron-sized holes (4.0, 5.5 
or 7.0 µm) (Fig. 7). An actuator moving at ultrasonic frequency (60 kHz) 
causes the membrane to vibrate which generates, depending on the mesh size, 
millions of precisely sized droplets in a size range of 3-15 µm (median 
diameter 5-7 µm) with narrow size distribution, mean diameter of 5-7 µm and 
medium size between 8 to 21 microns (Fig. 8).  
                          
 
 
Figure 7: Atomizing nozzle 
with a diameter of 4.0, 5.5 or 
7.0 µm 
 
Figure 8: Working principle of 




The droplets produced reach the drying chamber where, by vigorous agitation 
in the laminar flow of hot gas, are dried into solid particles of average size 
from 300 nm to 5 microns. Unlike what occurs with the Mini Spray Dryer, in 
which the particles less than 2 µm are not captured (Mosen et al. 2004), the 
mechanism of separation and collection of the particles in the Nano Spray 
Dryer is independent of the their mass and provides, due to their small size, 
the use of an electrostatic collector (Fig. 9). The latter consists of an internal 
star-shape electrode (cathode) and an external cylindrical-shape electrode 
(anode) between which an electric field is generated. The dried solid particles 
are electrostatically charged and are rejected by the cathode but attracted and 
collected by the anode. Hence, the particles are deposited on the inner wall of 
the electrode and are gently collected by means of a particle scraper.  
 
 
Figure 9: Electrostatic particle collector 
 
Compared to the traditional mini spray dryer, the nano spray dryer has the 
following advantages: 
- Production of submicronic particles or nanoparticles with a separation 
efficiency> 99%; 






- Minimum loss of product thanks to an excellent yield: up to 90% for sample 
quantities <100 mg; 




































































2.1 Cystic fibrosis: general background 
 
Cystic Fibrosis (CF) is the most common lethal inherited disease in 
Caucasians, occurring in approximately 1 in 3,000 newborns in the United 
States and Europe. The life expectancy of a child born with CF has gradually 
improved, but still only approaches 38 years (Elizur et al. 2008). CF is caused 
by mutations in the gene located on the long arm of chromosome 7 (7q31), 
containing 27 exons and which encodes the CF transmembrane conductance 
regulator (CFTR) (Cheng et al. 1990, Collins et al. 1990). 
 
 
Figure 10: CFTR protein 
 
The CFTR glycoprotein (Fig. 10), is a cyclic adenosine monophosphate 
(cAMP)-regulated low voltage chloride channel which is expressed in many 
epithelial and blood cells. It is composed of 1480 amino acids and it belongs to 
the ATP-binding cassette (ABC) transport protein super family. Although 
CFTR acts mainly as a chloride channel, it also regulates the function of other 
membrane proteins, including the inhibition of sodium transport through the 
epithelial sodium channel (ENaC) (Briel et al. 1998). Moreover CFTR has 
many other regulatory roles, including the regulation of the outwardly 
rectifying chloride channel, regulation of ATP channels, regulation of 





inhibition of endogenous calcium-activated chloride channels (Reisin et al. 
1994, Schwiebert et al. 1995, Stutts et al. 1995, Vankeerberghen et al. 2002, 
Mehta 2005). CFTR has also an important function in the transcellular 
secretion of bicarbonate (HCO3
¯
), an alkalizing agent that plays a crucial 
physiological role in pH buffering (Ehre et al. 2014). Reduced HCO3
¯
 
secretion in CF may be responsible for lowered epithelial surface pH, which 
has been shown to impede bacterial killing (Pezzulo et al. 2012) and increase 
mucus/mucin viscoelasticity (Celli et al. 2005, Georgiades et al. 2014).  
CF pathogenesis is characterized by the build-up of thick, sticky and viscous 
mucus which affects several organs, including the lung, the pancreas and the 
gastrointestinal and reproductive tracts. In particular, airway obstruction by 
thick mucus sets the stage for a vicious cycle of chronic bacterial infection, 
inflammation and airway damage which leads to progressive lung destruction 
and respiratory failure (Ramsey 1996). On the basis of these considerations, 
pulmonary disease seems to be the most challenging aspect of managing CF. 
 
2.2 CFTR Mutations 
 
To date, more than one thousand mutations in the CFTR gene have been 
identified in CF patients. The most common mutation (in 85% of CF patients) 
denoted as ΔF508, is a three-base deletion in the DNA sequence, causing the 
absence of an amino acid (phenylalanine) at position 508 of the protein 
sequence. 
As reported in Table 1, the mutations can be classified into several different 








Table 1: CFTR gene mutations 
 




I Shortened protein Trp1282X 7 
II 




Channel cannot be regulated 
properly 
G551D <3 
IV Reduced chloride conductance R117H <3 
V 
Reduced number of CFTR 




2.3 Infection and inflammation in CF airway 
 
Lungs of CF patients are often colonized or infected in infancy and early 
childhood with organisms, such as Pseudomonas aeruginosa, Staphylococcus 
aureus and Haemophilus influenza. Among these, P. aeruginosa is the major 
pathogen in CF lung; it express specific adhesins with which binds to cell 
receptors that permits to settle itself into the thick mucus. Once it sets up 
house in the respiratory tract, is hard to get rid of. (Russo et al. 2013) Indeed 
bacterial infections lead to epithelial surface damage and airway plugging, 
progressively impairing airway conductance, which results in a decline in 
pulmonary function (Lyczak et al. 2002) and consequent death in cystic 
fibrosis patients. 
Furthermore, components of the bacterial cell wall and flagella are the major 
activators of epithelial pro-inflammatory signaling causing a sustained 







Figure 11: Infection and inflammation status in CF airways 
 
The airway inflammation in CF appears to begin in early infancy in fact the 
bronchoalveolar lavage (BAL) studies from infants with CF shows high 
concentrations of neutrophils and pro-inflammatory mediators in the airways, 
even in the absence of identifiable pathogens (Nichols et al. 2008), indicating 
that inflammation can anticipate bacterial infection. 
The lung inflammation is characterized by a sustained accumulation of 
neutrophils, high proteolytic activity and elevated levels of cytokines and 
chemokines (Balough et al. 1995, Sagel et al. 2007). It is also suggested that 
mutant CFTR may itself contribute to defective regulation of the inflammatory 
response in lungs (DiMango et al. 1995, Venkatakrishnan et al. 2000, Weber 
et al. 2001) and may cause a higher pro-inflammatory state compared to non-
CF patients (Muhlebach et al. 2004). According to many researches, the 
airway inflammation is not only sustained, but also generated by continuous 
bacterial infections. This hypothesis is supported by the production of IL-8 in 
CF bronchial epithelial cells, in absence of an inflammatory stimulus 




in the CF lung epithelium remain partially understood. The synthesis of many 
pro-inflammatory mediators is promoted by the over activation of the 
intracellular transcription nuclear factor kappa-B (NF-kB) pathway, but it is 
not the only pathway implicated. While the release of IL-8 by CF lung 
epithelial cells was highly controlled by NF-kB, other pathways such as the 
mitogen-activated protein kinase/extracellular signal-regulated kinase 
(MAPK/ERK) and activated protein (AP-1) pathways have been found to be 
involved in the lung inflammatory processes in the presence of different 
inductors (Li et al. 2003, Verhaeghe et al. 2007, Boncoeur et al. 2008). In this 
context, pulmonary inflammation is an important therapeutic target in CF 
patients, aiming to limit and delay the lung damage.  
 
2.4 Mucus composition in CF patients 
 
The mucus covering the airway mucociliary epithelium is generally described 
as a biphasic layer composed of a periciliary liquid (PCL) in which the cilia 
beat and a more superficial gel layer which constitutes an efficient barrier 
against micro-organisms (Puchelle et al. 2002). Normally, the mucus is 
constantly cleared by the action of the mucociliary transport system which 
serves as a fundamental, innate defense mechanism for the lung to remove 
pathogens and debris (Cooper et al. 2013). 
In CF patients, the impaired electrolytic/fluid secretion caused dehydration of 
PLC and of the mucus layer, resulting in accumulation of dense and sticky 
mucus which seriously impairs the mucociliary transport and creates a 
favorable environment for bacterial survival and accumulation. The molecular 
framework and rheological properties of the CF mucus are provided by mucins 
and their heavily glycosylated domains which stiffen the mucin polypeptide 
(Gerken 1993) and provides specific ligands for bacterial adhesins (McGuckin 





Normally, pre-assembled mucin polymer are stored, condensed and dehydrate 





 that prevent mucins expansion by neutralization of the negatives 
charges of mucins. Upon the exocytosis onto the epithelial surface, to promote 





 ions, sequestered by HCO3
¯
 (Fig. 12). 
 
 
Figure 12: Possible mechanism for the expansion and solubilization of condensed mucins 
 
In Cystic Fibrosis, defective HCO3
¯
, due to a malfunction or lack of CFTR, 
impedes the normal hydration and expansion of mucin polymers and promotes 
stasis of mucus on the airway surface (Quinton 2010). The rheological 
properties of mucus are also influenced by alteration in lipid and DNA 
(released by neutrophils) contents. Girod et al. reported an increase in total 
phospholipids in CF secretions compared with normal secretions (Girod et al. 
1992). Furthermore, DNA-actin polymers network make the mucus thicker 
and more rigid than normal (Puchelle et al. 2002, Sriramulu et al. 2005, Shur 
et al. 2008, Voynow et al. 2009). Hence, the resulting CF mucus is more 
viscous, tenacious and less penetrable and make the drug delivery to the lung a 




delivery it is crucial to study both the ability of the drug to penetrate into or 
pass through the mucus layer and any drug–mucus interactions which may 
limit the bioavailability of API (Bhat et al. 1996, Khanvilkar et al. 2001, Yang 
et al. 2011). 
 
2.5 Current CF therapies 
 
The understanding of the different molecular mechanisms of altered 
functionality of CFTR provides the scientific basis for the development of 
drugs for the treatment of cystic fibrosis.  
Nowadays pharmaceutical research is currently proceeding on different fronts: 
- Gene and cell therapy; 
- Correction of pharmacological features CFTR; 
- Symptomatic treatment. 
 
2.5.1 Gene therapy 
 
Since the discovery of the CFTR gene in 1989, CF has been considered a 
prime candidate for gene therapy, especially for treating the airways, since 
topologically they are easily accessible. Clinical trials using different gene 
transfer agent were conducted, but no clinical benefit has far been recorded. 
Gene therapy may yet provide the best solution, but the technical difficulties 
led to search for alternative approaches.  
In vivo and in vitro studies on human CF nasal cells have indicated that 
boosting CFTR functional activity from less than 1% to as little as 5% of 
normal levels may greatly reduce disease severity or even eliminate the 
principal disease manifestations. Given the absence of other effective 
treatments, there has been an increasing interest in the possibility to restore the 





2.5.2 Modulation and correction of CFTR functionality 
 
As reported on www.cff.org growing attention is orientated to the 
development of new therapies designed to modulate and/or correct the 
function of the defective CFTR protein according to the different CF classes of 
mutation (Fig. 13).  
 
 
Figure 13: CFTR modulator drugs development  
 
The first product commercially available is Kalydeco®; it is a new oral 
medication approved by the FDA on January 31, 2012 for people with CF ages 
6 and older with the G551D mutation of CF. It aims to increase the activity of 
the defective channels normalizing the transport of ions through channels. 
Ataluren is a novel, small molecule compound that promotes the read-through 
of premature truncation codons in the CFTR mRNA, due to the “nonsense 
mutations”. Lumacaftor and VX-661 are new compound, called "corrector", 
designed to move defective CFTR protein to the proper place in the airway 
cell membrane and improve its function as a chloride channel. Vertex 
Pharmaceuticals (Boston, USA) submitted a New Drug Application in the U.S. 
and Europe for the approval of lumacaftor in combination with ivacaftor for 





QBW251 is a type of CFTR modulator called “potentiator”, similar to the drug 
ivacaftor, useful because it enhance the activity of normal channels already at 
the cell surface. 
N6022 is a new injectable compound that modulates the function of the 
defective CFTR protein and decreases inflammation in the lung. N6022 is the 
first of a new class of compounds that increase levels of an important 
signalling molecule in the body, called S-nitrosoglutathione (GSNO). Levels 
of GSNO have been shown to be decreased in people with CF. These novel 
compounds have been shown to increase the amount of CFTR that reaches the 
cell membrane and to stabilize CFTR so that its function can be improved. 
 
2.5.3 Management of Cystic Fibrosis 
 
In the absence of drugs for gene therapy or valid correction of the basic defect, 
currently the most common treatment of CF is symptomatic, aimed to reduce 
the intensity of the symptoms, slow the progress of the disease, prevent 
complications and, thereby, improve the quality of life for those who suffer 
from this severe disorder.  
Currently, CF treatment comprises respiratory physiotherapy, antibiotic 
therapy, nebulization with bronchodilators and mucolytic, making the 




The selection of the appropriate antibiotic for CF management is done on the 
basis of isolation of the bacteria through the sputum culture performed 
periodically by each patient and based on the specific sensitivity of these 





Different administration routes (oral, inhalation, intramuscular and 
intravenous) are available for the antibiotics treatment, however the inhalation 
route is gained growing attention in the new drug development (Fig. 14). 
 
 
Figure 14: Antibiotics already approved and under clinical studies for the management of CF 
 





are an inhalation solution of the 
antibiotic tobramycin indicated to treat people chronically infected with 
Pseudomonas aeruginosa. 2) Tobi Inhaled Powder® is the dry powder form of 
tobramycin that may allow a faster, more convenient dosing regimen. 
Cayston
®
 is an inhaled form of the antibiotic aztreonam that received FDA 
approval in 2010 for people chronically infected with Pseudomonas 
aeruginosa. Furthermore, three different antibiotics in form of liposome or dry 
powder (levofloxacin, amikacin and vancomycin) are in different steps of the 
drug development phases. 
Recently the European Medicines Agency approved Sodium Colistimethate, a 
polymyxin antibiotic effective against most Gram-negative bacilli, as inhaled 
solution (Corfinair®) and dry powder (Colobreathe®) to treat Pseudomonas 







Despite the inflammatory nature of the disease, neither oral nor inhaled 
corticosteroids were recommended for routine use in patients with CF, because 
of an unacceptable adverse event profile of oral corticosteroids, and absence of 
proof of efficacy for the inhaled medication (Balfour-Lynn et al. 2006, Flume 
et al. 2007). However, the excessive inflammatory response in the CF airways 
is gained growing attention of researchers and pharmaceutical companies in 
the developing of new anti-inflammatory products (Fig. 15). 
 
 
Figure 15: Anti-inflammatory approaches for the management of CF inflammation 
 
One of the first non-steroidal anti-inflammatory drugs (NSAIDs) tested in CF 
was ibuprofen, able to control some of the processes involved in the 
inflammatory cascade. It inhibits the migration of neutrophils into the lung 
tissue, the production of LTB4 and the activation of NF-kB. The evaluation of 
the use of this drug in cystic fibrosis, its efficacy and safety in high doses, is 
based on data from an American four years clinical study, published in 1995 
on the New England Journal of Medicine. The double-blind, placebo-
controlled study, had foreseen the oral administration of high doses of 
ibuprofen in patients aged 5 to 39 years with mild lung disease (forced 
expiratory volume in one second [FEV1]> 60%). It was observed that patients 





than those who were given placebo (- 3.57% per year). The beneficial effects 
were more evident in children between 5 and 12 years, in which the observed 
slower rates of decline in lung function (Konstan et al. 1995).  
The Alpha 1 Anti-trypsin is a drug that reached the phase 2 of the clinical trial. 
It is an aerosolized protease inhibitor derived from human plasma and has 
anti-inflammatory properties because protects tissues from enzymes released 
from inflammatory cells, especially neutrophil elastase. KB001-A is a 
humanized monoclonal Fab fragment that targets a Pseudomonas aeruginosa 
virulence factor. The mechanism by which KB001-A is predicted to provide 
clinical benefit for people with CF is by reducing local inflammation in the 
lung associated with this virulence factor. 
Finally, on April 2014, a phase 2 single centre trial has been completed with 
the purpose to determine whether sildenafil, already used in other types of 




Today, different approaches are used to keep the mucus thin and more fluid 
thanks to the improvement of the movement of salt in and out of cells. 
Hypertonic saline as an inhaled therapy and Bronchitol® (an inhaled dry 
powder form of mannitol [osmotic agent]) are believed to increase hydration 
of CF secretions thereby improving mucociliary clearance. Pulmozyme
®
 
(Dornase alfa) is a highly purified solution of recombinant human 
deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA. It 
is administered as an inhaled medication with the aim to reduce the high 







Airway clearance techniques 
 
There are many techniques used by patients with cystic fibrosis to augment 
clearance of tenacious airway secretions. These methods include percussion 
and postural drainage, active cycle of breathing techniques, airway-oscillating 
devices, high-frequency chest wall oscillation devices, and autogenic drainage 
(i.e., chest physiotherapy in which the patient does a series of respiratory huffs 
and coughs designed to move mucus from distal to proximal airways so it can 
be coughed out) (O'Sullivan et al. 2009). The active cycle of breathing 
technique includes relaxation and breathing control, forced expectoration 
technique, thoracic expansion exercises, and may also include postural 













































































SECTION A  
DESIGN AND DEVELOPMENT OF DPIs 
CONTAINING KETOPROFEN LYSINE SALT TO 


























































PART 1: MINI SPRAY-DRYING TECNOLOGY FOR THE 









Based on the article: Mariateresa Stigliani, Rita P. Aquino, Pasquale Del 
Gaudio, Teresa Mencherini, Francesca Sansone, Paola Russo “Non-steroidal 
anti-inflammatory drug for pulmonary administration: design and investigation 
of ketoprofen lysinate fine dry powders”. International Journal of 
Pharmaceutics. 2013, 448 (2013) 198– 204. 
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3A 1.1 Scientific background and research aim 
 
Cystic Fibrosis (CF), the most common lethal monogenic disorder in 
Caucasians, is caused by mutations in the gene encoding the CF 
transmembrane conductance regulator (CFTR). Clinically, CF is dominated by 
chronic lung disease, which is the main cause of both morbidity and mortality. 
In the lung of CF patients, the inflammatory response to bacteria seems to be 
greater and more excessive than in normal lung (Davis et al. 1996, Chmiel et 
al. 2003). The lung inflammation is characterized by a sustained accumulation 
of neutrophils, high proteolytic activity and elevated levels of cytokines and 
chemokines (Balough et al. 1995, Sagel et al. 2007). It is also suggested that 
mutant CFTR may itself contribute to defective regulation of the inflammatory 
response in lungs (DiMango et al. 1995, Venkatakrishnan et al. 2000, Weber 
et al. 2001) and may cause a higher pro-inflammatory state compared to non-
CF patients (Muhlebach et al. 2004). According to many researches, the 
airway inflammation is not only sustained, but also generated by continuous 
bacterial infections. This hypothesis is supported by the production of IL-8 in 
CF bronchial epithelial cell, in absence of an inflammatory stimulus 
(Venkatakrishnan et al. 2000) and by the similarity in pro-inflammatory 
cytokines of the bronco-alveolar lavage (BAL) of CF infants and adults 
(Armstrong et al. 2005). By contrast, in other studies (Rosenfeld et al. 2001, 
Weber et al. 2001, Zemanick et al. 2010) the BAL fluid of CF infants showed 
higher level of pro-inflammatory cytokines, compared to non-CF infants, even 
in absence of infection, thus indicating that inflammation can anticipate 
bacterial infection.  
In this context, pulmonary inflammation is an important therapeutic target in 
CF patients, aiming to limit and delay the lung damage. The oral use of 
corticosteroids as a pharmacological treatment is at present limited to acute 




pulmonary exacerbation, because of the heavy side effects experienced during 
a long-term administration. Moreover, corticosteroids seem to be ineffective 
given locally as inhalation products (Schiotz et al. 1983, Balfour-Lynn et al. 
1997). Non-steroidal anti-inflammatory drugs (NSAIDs) administered orally 
at high doses are able to slow down the rate of deterioration of forced expired 
volume (Konstan et al. 2007) (FEV1) and to reduce the amount of neutrophils 
in the lung (Konstan et al. 2003). However, the need of high doses of drug 
generates safety concerns for the long term therapy requested in CF patients. A 
pulmonary delivery of NSAIDs may reduce both inflammation and systemic 
exposure to the drug, thus avoiding its side effects. The propellant-free dry 
powder inhalers (DPIs), being formulated as one phase, solid-particle blends, 
are to be preferred thanks to their stability and easy processing. The aim of the 
present research was to develop respirable powders containing ketoprofen 
lysine salt (Klys) (Fig. 16), a well-known NSAID, and to produce a DPI able 
to fight the inflammatory status of CF airways by direct administration of the 
active pharmaceutical ingredient to the site of action.  
 
                     
Figure 16: Ketoprofen lysine salt 
 
Various dry powder formulations were designed, in which leucine was used as 
potential enhancer of flowability and spray drying as production technique. In 
order to fully investigate the ability of ketoprofen lysinate to reach the deep 
lung tissue, both the aerodynamic behavior of engineered particles and the 
drug permeation through a CF artificial mucus layer were evaluated. Finally, 
the in vitro effect on cell proliferation of pure ketoprofen and ketoprofen 
lysinate was compared to that of the engineered powders selecting CuFi1 cells 
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as a model of human airway epithelium of patients homozygous for ΔF 508 
CF causing mutation.  
 
3A 1.2 Manufacturing and characterization of powders 
 
Unprocessed ketoprofen and ketoprofen lysine salt are powders unsuitable for 
inhalation because of low flow property and stickiness. Currently, excipients 
approved for respiratory drug delivery are very limited in number (Pilcer et al. 
2010). The array of potential excipients is restricted to compounds that are 
biocompatible or endogenous to the lung and can easily be metabolized or 
cleared (Telko et al. 2005). Among potential excipients, recently we proposed 
leucine as potential enhancer of flowability and aerodynamic properties for 
sticky and high hygroscopic drugs (Prota et al. 2011, Aquino et al. 2012). 
Spray drying of acid ketoprofen with or without leucine and from different 
hydro-alcoholic feeds resulted in very low process yields and poor 
technological properties of the micronized powders. Better results were 
obtained starting from ketoprofen in its lysine salt form. Taking in account 
previous outcomes (Prota et al. 2011, Aquino et al. 2012), four different 
powder formulations were produced by spray drying in order to study the 
effect of leucine and organic co-solvent on particle formation and on their 
physico-chemical, aerodynamic and permeation properties. All batches were 
produced using the operative conditions reported in the experimental 
procedures (§4A 2). Particularly, Klys-1 and Klys-1a, containing only the 
active drug, were dried from water or 7/3 v/v water/isopropyl alcohol (IPA) 
mixture, respectively; batches Klys-2 and Klys-2a containing also 15% w/w of 
leucine, were prepared from water or 7/3 v/v water/isopropyl alcohol feeds, 
respectively.  
 




Table 2. Physical characteristics of spray dried particles: liquid feed composition, process 















O - 36.4 ± 3.5 7.47 (1.54) 
Klys-2 100% H
2
O 15 48.0 ± 5.6 5.58 (1.72) 
Klys-1a 70/30 H
2
O/IPA - 31.4 ± 5.2 4.58 (1.84) 
Klys-12a 70/30 H
2
O/IPA 15 78.0 ± 1.9 4.24 (1.80) 
 
As reported in Table 2, the organic co-solvent into the aqueous feed 
determined a dramatic reduction of the particle size, and this effect may be 
explained as a decrease of the surface tension in the liquid droplets. At the 
same time, the presence of leucine strongly improved the process yield (up to 
78% for Klys-2a), acting as enhancer of powder flowability, and contributed in 
reducing the mean volume diameter. Both effects combine to produce particles 
with a geometric diameter (D50) of about 4 µm and, therefore, potentially 
respirable and manageable for inhalation. Moreover, considering the 




vae DD   
the aerodynamic properties of a powder depend on particle shape (χ) observed 
by means of SEM analysis (Fig. 17) besides volume diameter (Dv) and density 
(ρ). In particular, the shape factor is defined as the ratio of the drag force on a 
particle to the drag force on a volume-equivalent sphere at the same velocity 
(Chow et al. 2007). An increase in particle surface roughness corresponds to 
an increase in shape factor and a consequent reduction in the aerodynamic 
diameter.  
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Figure 17: SEM pictures of spray-dried powders: a) Klys-1a batch containing API alone, and 
b) Klys-2a batch containing API and leucine as an additive. 
 
As well known, the morphology of spray-dried particles is strongly influenced 
by the solubility of the components and their initial saturation in the liquid 
feeds. Particles containing only the active compound (Klys-1a, Fig. 17a) are 




According to previous observations (Lechuga-Ballesteros et al. 2008, Prota et 
al. 2011), during the co-spray drying process, the saturation of the lower-
soluble component (leu) may increase faster than that of the hydrophilic one 
(Klys), due to the preferential evaporation of alcohol and the associated 
change in the solvent/co-solvent ratio. This led to the formation of a primary 
solid shell which collapsed, hence corrugated microparticles were formed.  
The addition of less soluble component (leu) in the liquid feed during the 
spray drying process led to crumpled particles showing many wrinkles (Klys-
2a, Fig. 17b) and, therefore, with increasing χ shape factor, which is likely to 
improve the aerodynamic performance. As reported elsewhere (Prota et al. 
2011), powders containing leucine showed higher tapped density values (0.78 
g/cm
3 
for Klys-2a).  
Concerning powders solid state, DSC analyses evidenced the loss of 
crystalline state of the drug as a consequence of the spray drying process. The 
thermogram of ketoprofen lysinate as raw material showed the phase transition 




peak at 174.18°C (Fig. 18), whereas leucine melts at higher temperature 
(295.76°C). 
 
Figure 18: Differential scanning calorimetry thermograms of ketoprofen lysinate and leucine 
raw materials, of their physical mixture and of the spray-dried powder Klys-2a. 
 
The absence of the endothermic peak that corresponds to the melting point of 
the crystalline drug in Klys-2a thermogram gives evidence of drug 
amorphisation occurring during the spray drying process. Moreover, in order 
to evidence any interaction between the drug and the excipient, a physical 
mixture containing ketoprofen lysinate and leucine (85:15 w/w) was prepared 
and analyzed by means of DSC. The thermogram of the physical mixture 
retained ketoprofen lysinate melting point (Fig. 18), suggesting the 
preservation of drug crystalline status, without evident change in the thermal 
behavior.  
It is well known that the effectiveness of an inhalation therapy, especially for a 
drug powder formulation, is dependent on factors that are related to the patient 
and the characteristics of the formulation but also to the device (Colombo et 
al. 2013). A breath-activated, reusable monodose device working with a size 3 
capsule was selected in the present research due to its optimal resistance rate, 
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ability to assure an effective particle disaggregation even with a moderate 
inspiration potency, as in the case of CF patients. When the capsule is pierced 
into the pulverization chamber by needles at the bottom and at upper side, the 
inhaled air creates a turbulence that shakes and twists the capsule, facilitating 
its empty.  
Such DPI containing ketoprofen lysinate engineered powders was investigated 
for the ability to reach the deepest stages of the in vitro impactor (ACI) after 
emission (§4A 1.5). 
 
Table 3: Aerodynamic properties of spray-dried powders after ACI experiments: Mass 

















 Klys-1 - n.d. n.d. n.d. 













 Klys-1a - 6.56 ± 0.43 16.7 ±1.2 6.80±1.4 
Klys-2a 15 4.39 ± 0.40 42.0 ± 3.9 11.2 ± 1.5 
 
Results (Table 3) indicated that the aerodynamic behavior of the powders was 
affected by the presence of the aminoacid. Confirming our previous 
observations (Prota et al. 2011, Aquino et al. 2012), leucine is a convenient 
pulmonary excipient able to act as a dispersibility enhancer and to increase the 
aerodynamic parameters FPF and FPD of powders formulations for inhalation.  
In fact, pure ketoprofen lysinate both as raw material or spray-dried from 
water (Klys-1) is unsuitable for inhalation because of the low flow property 
and stickiness; the powder did not come out from the capsule, hampering the 
aerosolization after actuation of the device (Table 3). Engineered particles 




produced by spray drying ketoprofen lysinate and 15% of leucine (Klys-1a) 
showed improved aerodynamic properties (FPF 28.5%, FPD 8.04 mg, Table 
3), thanks to the smaller diameter (Table 2) and the corrugated shape (Fig. 17). 
Interestingly, batch Klys-2a obtained by aqueous feed containing an organic 
co-solvent, achieved 42% of fine particles (FPF) that means the fraction 
potentially able to reach the deepest lung, after aerosolization through the 
monodose device. 
 
3A 1.3 Cytotoxicity in vitro on Cufi1 cells 
 
In order to establish whether the particle engineering may modify the toxicity 
profile of the drug having any cytotoxic or cytostatic effect, powders were 
assayed using bronchial epithelial cells bearing a CFTR F508/ F508 mutant 
genotype (CuFi1). CuFi1 cells were treated with increasing concentrations of 
ketoprofen lysine salt as raw material, Klys-1a, Klys-2a and pure ketoprofen 
(as control) in concentrations ranging from 0.1 to 1000 µM (expressed as 
ketoprofen content). The cell growth was monitored at 24 and 48 h using a 
colorimetric bromodeoxyuridine (BrdU) test. Results of the proliferation assay 
are reported in Figure 19.  
Pure ketoprofen as raw material showed a faint but significant toxic effect at 
concentrations higher than 1µM at 48 h and then 100 µM at 24 h. Its lysine 
salt and spray-dried formulations showed a reduction in cell proliferation only 
at very high concentrations. Moreover, a significant increase in viable cells (up 
to 65%) was observed only for spray-dried batches containing leucine, 
confirming previous observations (Prota et al. 2011) stating that the aminoacid 
improves the CF cell altered metabolism, reducing the toxicity observed for 
unprocessed drug. Thus, the particles engineering seems to reduce the 
cytotoxic effect of the active compound.  
 




Figure 19: Effect of ketoprofen, ketoprofen lysinate and engineered powders on CuFi1 cell 
proliferation and viability. Cells were treated for 48 h with: neat ketoprofen, neat ketoprofen 
lysinate, Klys-1a and Klys-2a spray-dried at concentrations from 0.1 µM to 1000 µM 
(expressed as ketoprofen content). Cell viability was determined by MTT assay. All data are 
shown as mean ± SD of three independent experiments, each done in duplicate (*P<0.05 and 
**P<0.01 vs control). 
 
3A 1.4 Conclusions 
 
The spray drying process allowed to obtain ketoprofen lysinate amorphous 
powders with good process yield, low cohesivity, and reduced geometric 
diameter starting from hydro-alcoholic solutions and a small amount of a safe 
natural excipient, leucine. Micronized powders containing ketoprofen in its 
lysine salt form and leucine showed improved aerodynamic properties, i.e. 
excellent emitted dose (>98%) and satisfying fine particle fraction (up to 
42%). Moreover, the particles engineering seems to reduce the cytotoxic effect 
of the drug on bronchial epithelial cells bearing a CFTR ΔF508/ΔF508 mutant 
genotype. These results make the ketoprofen lysinate based DPI a very 
promising product for the management of pulmonary inflammation in CF 




patients. Alternative to conventional routes of administration, a pulmonary 
local delivery of NSAIDs may induce an inflammation control reducing the 
systemic exposure to the drug and, consequently, its side effects. 
  












PART 2: NANO SPRAY-DRYING TECNOLOGY FOR THE 










Based on the article: Aquino Rita P., Stigliani Mariateresa, Del Gaudio 
Pasquale, Mencherini Teresa, Sansone Francesca Russo Paola “Nano-spray 
drying as a novel technique for the manufacturing of inhalable NSAID 
powders”. The Scientific World Journal, Volume 2014, Article ID 838410, 7 
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3A 2.1 Scientific background and research aim 
 
Spray drying is a one-step process widely used to obtain a powder from a 
solution, suspension or emulsion, with the possibility to modulate powder 
physical and technological properties in relation to the specific use (De Cicco 
et al. 2014, Hoe et al. 2014). In particular, in the field of formulations for 
inhalation, the appropriate tuning of process parameters may give the 
possibility to modify physical properties such as powder density, particle 
morphology, surface and porosity, therefore dramatically influencing the 
aerodynamic performance for nasal and lung formulations (Russo et al. 2006, 
Dalpiaz et al. 2008, Prota et al. 2011, Buttini et al. 2012, Balducci et al. 2014). 
Recently, an innovative spray dryer was developed, which claimed three 
unique patented technologies: a laminar airflow to decrease sample loss with 
minimal dead volume; a spray head system to produce small particles in a very 
narrow size distribution and an electrostatic particle collector to obtain high 
yields and recover even the smallest particles (Li et al. 2010, Heng et al. 2011, 
De Cicco et al. 2014).  
Differently from standard spray drying apparatus characterized by a pneumatic 
nozzle, in this case liquid feed droplets are generated by a piezoelectric 
system, vibrating a thin, and stainless steel membrane. The membrane features 
a series of precise micron-sized holes (spray meshes of 4.0, 5.5 or 7.0 μm hole 
size): after an ultrasonic frequency (60 kHz), membrane vibrates, ejecting 
precisely sized droplets at high speed. Moreover, the dried solid particles are 
electrostatically charged and collected in an electrostatic collector, so that their 
separation seems to be independent of particle mass as in standard cyclones 
and to allow collection of smaller particles; consequently, process yield may 
be improved (Schmid et al. 2011, Baba et al. 2012).  
Among drug formulations, powders for inhalation are certainly those whose 
efficacy depends mainly on the particle size, strongly influencing the aerosol 




deposition (Parlati et al. 2009, Aquino et al. 2012). Thus, the possibility to 
reduce and control particle diameter compared to standard spray drying 
system, makes the nano-spray drying a promising technology for the 
production of inhalation powders, as confirmed by recent studies (Lee et al. 
2011, Beck-Broichsitter et al. 2012).  
The aim of this research was to evaluate the potential of this innovative 
technology for the manufacturing of a dry powder for inhalation containing 
ketoprofen lysinate (Klys) as model drug for inflammation control in Cystic 
Fibrosis (CF) patients. Respirable engineered particles of this NSAID were 
previously prepared by co-spray drying the active pharmaceutical ingredient 
(API) and leucine (leu) as safe excipient. The use of aminoacid as a powder 
dispersibility enhancer showed no influence both on drug dissolution and 
permeation and on viability of ΔF508 CF (CuFi1) cells (Stigliani et al. 2013). 
With this aim we produced several ketoprofen lysinate and leucine powder 
batches by nano-spray dryer, studying the influence of process parameters on 
yield, particle properties (size distribution, morphology) and, mainly, 
aerodynamic properties of the resulting powders. 
 
2A 2.1 Manufacturing and characterization of powders. 
 
Several ketoprofen lysinate and leucine powders were produced by nano-spray 
drier, with the aim to evaluate the effect of different operative conditions on 
physico-chemical properties and aerodynamic performance of microparticles 
produced. On the basis of our previous research (Stigliani et al. 2013) in the 
first series of experiments Klys/leu ratio and composition of the hydro-
alcoholic feed were set at 85/15 w/w and 70/30 v/v water/IPA, respectively. 
Powder batches and main characteristics are summarized in Table 4.  
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Table 4 Klys/leu powders produced by nano-spray drier: process parameters, yield, drug 





















#1 110 5% 7 87.0 ± 2.8 6.6 (1.7) 79.4 ± 1.5 1.11 
#2 110 3% 7 82.3 ± 3.2 6.2 (1.7) 77.0 ± 2.1 1.11 
#3 110 5% 4 62.3 ± 2.8 3.2 (1.7) 82.9 ± 0.8 0.13 
#4 110 3% 4 43.0 ± 4.2 - a 79.2 ± 3.1 0.10 
#5 70 5% 4 77.6 ± 1.6 2.4 (1.7) 75.3 ± 0.4 0.06 
#6 70 3% 4 56.7 ± 1.0 - a 78.5 ± 1.1 0.06 
#7 70 1% 4 52.1 ± 1.8 - a 80.1 ± 1.3 0.08 
#8 60 5% 4 27.9 ± 7.1 - a 73.5 ± 1.2 0.04 
#9 70 5% 5.5 68.6 ± 1.9 3.1 (2.4) 72.4 ± 0.6 0.33 
a
 powder stickiness prevented measure.  
 
The first process variable considered was the dimension of spray head which 
at the beginning was set at 7µm, as to nozzle diameter (batch #1 and #2). Both 
liquid feed processed containing a powder/solid concentration from 3 to 5% 
w/v led free flowing powders with a very high yield (>80%) were produced; 
however dimensional analysis showed particles in a dimensional range 
expected to be not suitable for inhalation (D50>6µm). Therefore, with the aim 
to obtained particles with a smaller geometric diameter, the 4µm nozzle was 
chosen, exploring the effect of both temperature and total solid concentration 
in the feed on powder properties (Table 4). Generally, using a 4µm nozzle, 
lower powder concentration (1-3% w/v, batch #4, #6 and #7) in the liquid feed 
led to a sticky product, difficult to handle and to test as to particle size and 
aerodynamic performance. Accordingly, for these powders, process yields 
were not satisfactory. More dense feeds, containing higher solute 
concentration (5% w/v of ketoprofen lysinate and leucine, batch #3 and #5) 




improved process yield, producing powder in a good dimensional range (D50 
2.4 - 3.2µm). Moreover, it is notable that nano-spray allows to considerably 
reduce the inlet temperature from 110°C up to a value of 70°C, in comparison 
to standard spray drying technology, and this appears as a very important 
result for the processability of thermolabile active compounds.  
Morphology study evidenced that particles where irregularly shaped but well 
separated from each other (Fig. 20 a, b) when produced by means of a 7µm 




Figure 20: SEM pictures of powders obtained from a) #2 (110°C, 3% w/v, 7µm nozzle), b) #1 
(110°C, 5% w/v, 7µm nozzle), c) #4 (110°C, 3% w/v, 4µm nozzle), d) #3 (110°C, 5% w/v, 
4µm nozzle).  
 
Powders obtained using a 4µm nozzle, were sensibly smaller in diameter as 
clearly visible in SEM picture (Fig. 20 c, d), but only the highest feed 
concentration (5% w/v) led to particles not agglomerated (Fig. 20 d, #3), as 
predictable from very low process yield and powder stickiness.  
In vitro deposition behavior of non-sticky powders was evaluated using the 
monodose DPI model 7 as device for the dose erogation and the Andersen 
Cascade as impactor. The emitted dose for all nano spray-dried batches was 
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almost 100% of the charged formulation, indicating a very efficient de-
aggregation of powders by means of the selected device (Table 5). The dose 
recovered from the impactor was higher than 80% in all cases (data not 
shown). As expected from powders geometric diameter (>6 µm) (Table 4), 
batches produced by means of a 7µm nozzle showed poor aerodynamic 
properties, with a FPF <30%.  
 
Table 5: Aerodynamic properties of nano-spray-dried Klys/leu (15% leu, 30% IPA) powders 
after ACI experiments: Emitted dose (ED) Mass Median Aerodynamic Diameter (MMAD), 














#1 5% N7T110 99.2 ± 0.1 5.69 ± 0.23 21.9 ± 2.5 6.27 ± 0.5 
#2 3% N7T110 99.2 ± 0.1 5.44 ± 0.55 29.5 ± 2.3 8.16 ± 0.24 
#3 5% N4T110 99.1 ± 0.1 4.25 ± 0.12 50.4 ± 1.9 12.7 ± 1.1 
#5 5% N4T70 100.0± 0.1 3.72 ± 0.07 66.3 ± 1.0 16.9 ± 0.6 
#6 3% N4T70 96.7 ± 4.2 6.25 ± 0.11 31.6 ± 1.6 7.85 ± 1.2 
#9 5% N5.5T70 97.3 ± 1.0 4.58 ± 0.14 45.6 ± 2.2 12.2 ± 1.3 
 
Among powders produced by means of the 4µm nozzle, very interesting 
aerodynamic properties were evidenced for batch #5 showing a FPF of 66.3%, 
together with the smallest geometric diameter and a high process yield 
(5%N4T70, Table 5).  
Figure 21 shows the amount of drug deposition on the throat, on the stages 1 
to 7 and on the filter, expressed as percentages of the total powder recovered 
from the impactor. Confirming its excellent aerodynamic performance, batch 
#5 was characterized by a very low deposition on the throat and onto the upper 
stages of the Andersen Cascade Impactor (Fig. 21). 





Figure 21: Andersen cascade impactor deposition pattern after the aerosolization of powder 
(batch #5) sprayed with a 4 µm nozzle at 70°C (#5% N4T70). 
 
However, in addition to an improvement of the aerodynamic properties of the 
powders, the reduction of nozzle size from 7 to 4µm led also to a dramatic 
increase in process time (Table 4), moving from 1.11 to 0.06 ml/min of liquid 
feed processed. The portion of liquid pumped into the atomization head and 
not sprayed went back to the feed container in a continuous loop, exposing the 
sample to the inlet temperature for very long times. In the case of Klys, this 




Figure 22: Picture of Klys/leu powders after nano-spray process using 7 (#1, a) and 4µm 
nozzle (#5, b). 
 
Several attempts were pursued with the purpose to reduce thermal stress of the 
processing fluid (i.e. use of ice bath, reduction of batch volumes), with 
unsatisfactory results. Finally, with the aim to reduce viscosity at the nozzle 
and increase droplet formation efficiency, nozzle was dressed with a film of 
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surfactant dipping the vibrating membrane into a span 80 n-hexane solution 
(0.05% w/v) and allowing the solvent to evaporate. As expected, the thin film 
of surfactant changed the influence of process parameters on powder 
properties, so that a new set-up of the apparatus was necessary. The main 
process variables considered were total powder concentration (ranging from 5 
to 7% w/v), drug/leu ratio (from 85/15 to 90/10 w/w), and water content (from 
70 to 100% v/v) in the hydro-alcoholic feeds. The characteristics of the main 
batches prepared with the surfactant treated nozzle are summarized in Table 6.  
 
Table 6: Process parameters and physical characteristics of Klys/leu particles sprayed through 



















#5a 5% 15% 70/30 33.1 ± 9.2 -a 0.21 
#5b 6% 15% 70/30 45.1 ± 3.5 -a 0.21 
#5c 5% 10% 70/30 74.8 ± 2.5 - a 0.21 
#5d 6% 10% 70/30 75.2 ± 1.0 3.01 (1.80) 0.21 
#5e 7% 10% 70/30 18.2 ± 7.5 - a 0.21 
#10 6% 15% 100/0 71.7 ± 1.2 3.14 (1.86) 0.14 
#11 6% 15% 90/10 75.3 ± 0.5 2.84 (1.63) 0.42 
#12 6% 15% 80/20 68.7 ± 2.6 2.94 (1.90) 0.06 
#13 6% 10% 90/10 76.2 ± 3.1 2.52 (1.90) 0.21 
#14 6% 10% 100/0 65.5± 1.5 3.14 (1.69) 0.10 
a
 powder stickiness prevented measure.  
 
The surfactant layer on the spray head membrane generally caused a speeding 
up of the atomization (up to 0.42 ml/min) and a consequent reduction in 
process time.  




As evidenced by SEM pictures reported in Figure 23, the amount of leucine 
influenced particle morphology and surface properties, both for aqueous and 
hydro-alcoholic liquid feed processed. In particular, particles from powders 
containing 10% leucine were spherical in shape (Fig. 23 a,b), while particles 
from powders containing higher amount of leucine (15%, Fig. 23 c,d) were 
wrinkled and corrugated. This is a very important effect, since an increase in 
particle surface roughness corresponds to an increase in shape factor and a 




Figure 23: SEM pictures of powders obtained from a) 14# (6% w/v, Water/IPA 100/0 v/v, 
10% leu), b) #13 (6% w/v, Water/IPA 90/10 v/v, 10% leu), c) #10 (6% w/v, Water/IPA 100/10 
v/v, 15% leu), d) #11 (6% w/v, Water/IPA 90/10 v/v, 15% leu).  
 
Finally, concerning powder technological properties, improvements were 
obtained by increasing the concentration of dry content up to 6% and/or 
reducing the amount of organic solvent in the liquid feeds (from 30 to 0% v/v), 
resulting in both cases an increase of solution viscosity. In particular, batches 
11 and 13 produced from 90/10 v/v hydro-alcoholic solutions were white and 
free-flowing powders: among these, batch 11 containing 15% w/w of leucine, 
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represented the most promising product, in terms of process efficiency (0.42 
ml/min of liquid feed processed and 75.3% yield). 
 
Table 7: Aerodynamic properties of Klys/leu powders sprayed through a surfactant treated 
nozzle (70°C, 4µm nozzle, 6% w/v feed) after ACI experiments: Emitted dose (ED) Mass 
Median Aerodynamic Diameter (MMAD), Fine Particles Fraction (FPF) and Fine Particle 

















#5d 10% 70/30 98.4 ± 2.9 4.25 ± 0.12 54.4 ± 0.3 15.8 ± 0.4 
#10 15% 100/0 100.1 ± 0.1 4.02 ± 0.05 54.8 ± 1.1 18.2 ± 0.7 
#11 15% 90/10 99.7 ± 0.3 3.83 ± 0.02 60.9 ± 1.2 18.0 ± 0.4 
#12 15% 80/20 99.9 ± 0.2 4.19 ± 0.20 55.3 ± 2.5 16.6 ± 1.1 
#13 10% 90/10 100.8 ± 0.1 4.31 ± 0.22 49.9 ± 3.2 15.5 ± 0.9 
 
Besides process efficiency, DPI containing #11 presented also the highest 
fraction of drug with an aerodynamic diameter less than 5µm, as reported in 
Table 7. Increasing particle roughness and corrugation, leucine positively 
influenced powders aerodynamic performance, with FPF values up to 60.9%.  
 
3A 2.2 Conclusions 
 
The nano-spray drier system seems to be an efficient alternative to standard 
spray drying in formulating dry powders with reduced geometric diameter and 
increased aerosol performance. Certainly, the accurate tuning of process 
variables is necessary to allow the preparation of fine powders with physico-
chemical and aerodynamic properties suitable for inhalation. In the case of 
ketoprofen lysinate, using the smallest nozzle (4µm) process times were 
considerably high, resulting in brownish powders. To reduce the process time 
and gain a good yield, a surfactant thin film covering the nozzle was required, 
with the aim to increase drug solution passage through the micron-sized holes 




of the membrane, accelerating powder production. The selection of process 
variables allowed us to obtain a white powder with satisfying aerosol 
performance and able to release 18 mg of fine particles after one actuation of 
the monodose device.  
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3B Scientific background and research aim 
 
Apart from deposition, systemic or local pharmacological activity of an 
inhalation product depends on drug dissolution into the biological fluids lining 
the lung. Consequently, during the development of a new DPI, the in vitro 
dissolution profile of the formulated drug is an essential way of anticipating its 
in vivo behavior. Official Pharmacopeias provide standardize methods for the 
dissolution test of solid or semisolid, oral or dermal dosage forms, well 
established both for quality control testing and for prediction of in vivo drug 
release. However, no regulatory requirements for testing medications for 
inhalation are available to date and this gap must be bridged (Russo et al. 
2013). In 2008, the Inhalation Ad Hoc Advisory Panel of USP reviewed all 
current literature and, considering the strengths and limitations of the 
published procedures for in vitro dissolution testing of inhalation dosage 
forms, it concluded that there was no compelling evidence that dissolution was 
“kinetically and/or clinically crucial for currently approved” inhaled products 
(Riley et al. 2012). Nevertheless, in the recent years there has been growing 
interest of academic and as well as industrial researchers in the development 
of in vitro techniques to determine the dissolution profile of products for 
inhalation. Different apparatus have been used in published reports of 
dissolution testing of inhaled products, namely, USP 2 paddle apparatus, 
custom-built flow-through apparatus and mainly diffusion-controlled cell 
systems (Davies et al. 2003, Son et al. 2009).  
The definition of such a standardized method is a tricky step, due to the 
peculiar anatomy of the deep respiratory tract. The test conditions must reflect 
the pulmonary environment, particularly the thin liquid layer on which the 
inhaled particles impact (10–20 ml/100 m
2 
of surface). Moreover, in some 
pathologies, such as cystic fibrosis (CF), the presence of a thick viscid mucus 
may reduce the effective drug delivery to the target tissues. More than in other 




pathologies, the study of drug–mucus interaction is a crucial step in CF, to 
check the ability of the drug to penetrate and distribute through airways 
surface fluids.  
Various methods and models for estimating permeability of drugs potentially 
delivered as pulmonary aerosol, have been proposed e.g. Side-By-Side® 
diffusion apparatus (Bhat et al. 1995, Agu et al. 2011), as well as Franz type 
vertical dissolution cell (Donnelly et al. 2007) using a modified configuration 


























PART 1: PERMEATION PROPERTIES TROUGHT CF 
MUCUS MODEL OF GENTAMICIN AND KETOPROFEN 
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inflammatory drug for pulmonary administration: design and investigation of 
ketoprofen lysinate fine dry powders”. International Journal of 
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Crescenzi, Amalia Porta, Rita P. Aquino, “Gentamicin and leucine inhalable 
powder: What about antipseudomonal activity and permeation through cystic 
fibrosis mucus?. International Journal of Pharmaceutics 440 (2013) 250– 255 
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3B 1.1 Research aim 
 
With the aim to investigate dissolution and permeation properties of dry 
powders for inhalation developed during the PhD project an in vitro method 
based on Franz-type diffusion equipment was proposed. 
In the first part of the study the experiments were performed dusting the 
powder directly onto a synthetic membrane, to explore the effect of particle 
engineering and excipient on the drug dissolution/permeation. 
Afterwards, to better mimic the CF pulmonary environment, permeation 
properties of the drug from DPIs were evaluated spreading the powder on a 
thin layer of artificial CF mucus poured on the membrane. To this purpose, a 
mucus model was prepared taking in account physico-chemical composition 
and rheological behavior of CF bronchial sputum. 
 
3B 1.2 Permeation properties of gentamicin/leu DPIs 
 
Aminoglycosides, such as gentamicin sulfate (G) (Fig. 24), are indicated in the 
management of acute exacerbations of CF as well as in the control of chronic 
infection and the eradication of P. aeruginosa infections. Moreover G has 
shown the ability to partially restore the expression of the functional protein 
CFTR (cystic fibrosis transmembrane conductance regulator) in CF mouse 
models bearing class I nonsense mutations (Wilschanski et al. 2000, Clancy et 
al. 2001, Du et al. 2002, Wilschanski et al. 2003).  
 
·H2SO4  
Figure 24: Gentamicin sulfate  




In a previous study (Aquino et al. 2012) four out of twenty G dry powders 
designed and having satisfying aerosol performance were produced by spray-
drying hydro-alcoholic feeds with 30% (v/v) of an organic co-solvent 
(isopropanol, IPA or ethanol, ET). GET3 and GISO3 contained pure G; 
GET3-leu15, GISO3-leu15 were manufactured with G and 15% (w/w) of leu, 
which was the aminoacid concentration giving rise to the best respirability 
parameters, as reported in Table 8.  
 
Table 8: G dry powders: composition, yield of the spray drying process, particle size 
distribution and aerodynamic properties (evaluated as MMAD mass median aerodynamic 
diameter, FPF Fine Particle Fraction and FPD Fine Particle Dose) after Andersen cascade 



























 GET3 - 74.8 ± 3.5 
4.01 
(1.82) 
n.d. n.d. n.d. 
GET3-
leu15 15 
68.2 ± 2.9 
4.16 
(1.71) 












 GISO3 - 85.5 ± 1.1 
4.24 
(1.97) 
6.6 ± 0.4 16.7 ±1.2 6.8 ± 1.4 
GISO3-
leu15 
15 82.0 ± 1.5 
3.90 
(1.62) 
4.4 ± 0.4 42.0 ± 3.9 11.2 ± 1.5 
 
The less polar co-solvent isopropanol led to higher process yields compared to 
ethanol whereas leu had no positive effect on the quantity of powder recovered 
from the spray drier. G and leu content in the final spray-dried powders 
determined by HPLC (almost 100% of the theoretical dose, data not shown), 
and particle size analysis by LLS (D50 3.90-4.24 µm) indicated optimized 
process conditions. However, GET3 and GISO3, produced without leu, were 
highly cohesive and too sticky and, therefore, presented very poor 
aerosolization and deposition performance (FPF <9%), evaluated by ACI 
 Results and Discussion 
73 
 
experiments. The presence of 15% leu dramatically increased FPF (>40%) and 
FPD values (>47mg) (Table 8). In particular, batch GISO3-leu15 dried from 
water/isopropanol feed showed the best inhalation profile and the ability to 
deliver high fraction dose to the lung, emitting 56.4 mg of fine G after one 
device actuation.  
With the aim to study G permeability and how the aminoacid in the drug 
formulation may influence G dissolution and permeation through a synthetic 
membrane, we selected Franz-type vertical diffusion cells equipment.  
In a first set of experiments, buffer permeability was evaluated by means of 
Franz cells in a standard configuration (Fig. 25), spreading the powder directly 
on a nitrocellulose membrane in the donor compartment as described in the 
experimental procedures (§4B 5).  
 
 
Figure 25: Franz cell used in permeation studies: a) standard configuration with one dosage 
wafer housing the drug formulation; b) modified configuration with three dosage wafers 
housing mucus and drug formulation.  
 
Results are reported in Figure 26. As already known, drug dissolution is 
influenced by the rate at which solvent-drug interactions overcome the 
cohesive forces between bioactive molecules (Davies et al. 2003). Therefore, 
as expected, powders containing neat G, a very soluble and high polar drug, 
showed a typical diffusion controlled release, not influenced by the dissolution 
process (Fig. 26, open squares). The addition of leu, amino-acid with a 
lipophilic side chain, must reduce powder wettability and, consequently, the 
 




affinity between the solid and the medium. Accordingly, the drug permeation 
rate from G-leu batches (Fig. 26, black squares), was reduced and this effect 
may be due to a slower dissolution of the drug once in contact with the wet 
membrane surface. No difference in buffer permeability was observed for 
powders dried from water/ethanol (Fig. 26a) or water/isopropanol (Fig. 26b) 
feeds.  
 
Figure 26: Buffer permeation profile of gentamicin through nitrocellulose membrane of dry 
powders with (GET3-leu15 and GISO3-leu15, black squares) or without (GET3 and GISO3, 
open squares) leucine and spray-dried from a) water/ethanol or b) water/isopropanol, 7/3 v/v. 
 
The buffer permeability is useful to estimate diffusivity through an aqueous 
medium and provides a baseline for successive experiments. In order to better 
mimic the pulmonary environment, G permeability in a synthetic mucus layer 
was evaluated, too. This model was prepared taking in account physico-
chemical composition and rheological behavior of CF bronchial sputum 
(Livraghi et al. 2007, Rubin 2007). The gel-forming glycoprotein mucin and 
other typical constituents such as DNA, salts, surfactant, lipids, proteoglycans, 
are considered responsible for the viscoelastic properties and able to reduce 
drug permeation (Bhat et al. 1996, Khanvilkar et al. 2001, Yang et al. 2011). 
Preliminarily, we prepared a CF simplified model (AM-) as described 
elsewhere, (Sriramulu et al. 2005). However, as already noticed by other 
authors (Yang et al. 2010), the resultant gel was too fluid compared to CF 
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sputum specimens (viscosity ~ 2 Pa×s at 0.16 Hz) (Shur et al. 2008) and 
passed through the membrane pores during the permeation studies. 
Experimentally, we found no more mucus retained on the membrane surface 
after 60 min. Hence, aiming to increase mucus viscosity while maintaining its 
basic composition, the inert rheological modifier hydroxyethylcellulose (HEC 
1% and 1.5% w/v) was added, obtaining AM1 and AM1.5, respectively. The 
viscosity properties of the mucus models developed were evaluated by means 
of a rotational viscometer as described in the experimental procedures (§4B 3). 
AM1 and AM1.5 showed a rheological behavior typical of pseudo-plastic fluids 
(Fig. 27), with a viscosity reduction after shear stress increase similar to that 
observed for whole sputum of patients affected by CF (Shur et al. 2008).  
 
Figure 27: Viscosity values (η) versus oscillation frequency (ω) for synthetic CF mucus 
model AM1 (circles) and AM1.5 (triangles) 
 
Both mucus samples were retained on the membrane surface throughout the 
experiment, without modifying aspect or viscosity during 180 min of testing 
and allowing the fulfilment of the permeation study. 
In the second set of experiments, G permeability was evaluated using the 
Franz cells in a modified configuration (Fig. 28) (Donnelly et al. 2007) 
interposing AM1 or AM1.5 between the nitrocellulose membrane and the drug 



















Figure 28: Modified configuration of Franz cell used in permeation studies with three dosage 
wafers housing mucus and drug formulation.  
 
Results are reported in Figure 29a,c for AM1 and Figure 29b,d for AM1.5, 
(batches with leu, black squares, without leu, open squares) in comparison to 
buffer permeation profile (triangles).  
 
 
Figure 29: Mucus permeation profiles of gentamicin from powders with (GET3-leu15 and 
GISO3-leu15, black squares) or without (GET3 and GISO3 open squares) leucine and dried 
from a-b) water/isopropanol, c-d) water/ethanol and 7/3 v/v; through a-c) mucus AM1 and b-d) 
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AM1 and even more AM1.5 reduced significantly G permeability, compared 
with the corresponding buffer permeability. Moreover, leu had only a faint 
influence on G permeation properties. This result seems to be a key issue; the 
selected excipient does not interfere with the ability of the drug to permeate 
through a mucus layer. The observed decrease in drug transport needs to be 
considered for compounds that must cross a mucosal surface prior to action or 
absorption; however, it is an interesting property in the case of antibiotics, 
such as G, which must be locally bioavailable for acting against bacteria 
colonizing mucus layer. 
 
3B 1.3 Permeation properties of ketoprofen lysine salt/leu from DPIs 
 
The dissolution/permeability of ketoprofen lysine salt from the engineered 
particles (prepared as reported in §3A 1.2), was evaluated too, using the 
method based on Franz-type diffusion equipment as described in the 
experimental procedures (§4B 5).  
Dry powder formulations were produced using mini spray drying technique. 
Batch Klys-1a, containing only the active drug was dried from water and Klys-
2a containing also 15% w/w of leucine, was prepared from water or 7/3 v/v 
water/isopropyl alcohol feed. 
Initially, Franz-type cells assembled in the traditional configuration were used 
to follow the drug permeation in the receiving compartment (phosphate buffer 
0.05 M, pH 7.4) dusting the powders (Klys-1a and Klys-2a) directly onto the 
wet membrane. Results are reported in Figure 30. The spray-dried pure drug 
(Klys-1), due to the high drug solubility (water solubility: 67.7 ± 5.1 mg/ml) 
showed a typical diffusion controlled release, not influenced by the dissolution 
process. Solvent-drug interactions may easily overcome the cohesive forces 
between very polar and soluble drug molecules. 




              
Figure 30: Buffer (triangles) and mucus (circles) permeation profiles from ketoprofen lysinate 
powders produced with leucine (Klys-2a; full triangles and circles) or without leucine (Klys-
1a; empty triangles and circles). 
 
The addition of a less polar additive such as leucine (water solubility 22.4 ± 
0.2 mg/ml) had no effect on the drug permeation process, as evidenced by the 
perfectly overlapped permeation profiles (triangles) of Klys-1a and Klys-2a. In 
a second set of experiments, the drug permeability was evaluated interposing a 
mucus layer between the powder and the membrane, in order to study the 
effect of the mucus on the permeation properties. The artificial mucus with 
composition similar to that of CF patient and containing hydroxyethylcellulose 
as inert thickening agent was prepared as described in §4B 2. 
Results reported in Figure 30 (Klys-1a empty circles; Klys-2a full circles) 
showed that the mucus layer slowed down ketoprofen lysinate dissolution and 
permeation, acting as a physical barrier to the permeation of the drug. 
Moreover, the presence of the aminoacid, leucine, did not influence the 
velocity and the amount of active compound able to dissolve and permeate 
into the receiving compartment through the mucus layer. It is well known that 
the drug contact with lung fluid is an early stage in pulmonary 
pharmacokinetics, before absorption or distribution can take place.  
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3B 1.4 Conclusions 
 
A synthetic CF mucus and Franz-type cells may be useful to investigate drug–
mucus interaction, a critical event that puts the efficacy of inhaled medications 
at risk. Starting from literature data, we improved a basic mucus model using 
an inert rheological modifier to obtain a fluid with rheological properties 
similar to CF mucus and able to overstay the membrane surface throughout the 
experiment time. The method herein proposed was applied to investigate the 
permeation of respirable engineered powders containing gentamicin sulfate or 
ketoprofen lysine salt as drug and leucine as dispersibility enhancer.  
The use of the synthetic mucus in the permeation studies evidenced that the 
very polar active compounds formulated as a fine powder retain their ability to 
dissolve and permeated through an artificial mucus layer, with no influence of 
the excipient. Moreover the present research suggests that leucine is a very 
interesting additive for pulmonary use, able to enhance the aerodynamic 
performance of dry powders but does not affect the dissolution of the drugs. 
 
  


















PART 2: RHEOLOGICAL PROPERTIES OF CYSTIC 
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3B 2.1 Scientific background and research aim  
 
In CF patients, the impaired electrolytic/fluid secretion caused the build-up of 
thick and sticky mucus-gel responsible of both airway obstruction and loss of 
pulmonary function. The molecular framework and rheological properties of 
the CF mucus are provided by mucins and their heavily glycosylated domains 
which stiffen the mucin polypeptide (Gerken 1993) and elevated DNA content 
which can exhibit specific interactions with mucin leading to an increase of 
elasticity of the mucus solutions (Bhat et al. 1996). Moreover, many studies 
indicated that that CF transmembrane conductance regulator (CFTR) is 
required for bicarbonate (HCO3
¯
) transport and that HCO3
¯
 is critical for 
normal mucus formation (Garcia et al. 2009, Gustafsson et al. 2012). Indeed, 
defective HCO3
¯
, impedes the normal hydration and expansion of mucin 
polymers and promotes stasis of mucus on the airway surface (Quinton 2010).  
Hence, this part of research aimed to study rheological properties of human 
bronchial mucus obtained from CF patients, thanks to the collaboration with 
U.O.C. Genetica Medica and Centro Fibrosi Cistica of Giannina Gaslini 
Institute of Genoa.  
With the intent to understand the mechanisms that occur when inhaled micro- 
and nano-particles are deposited on the mucus and to check the ability of the 
drug to penetrate through the mucus, permeation of ketoprofen lysinate (Klys) 
as Dry Powder Inhaler was evaluated. 
Finally, the effect of a saline solution containing high concentration of 








3B 2.2 Rheological properties of CF mucus patients 
 
For CF mucus, oscillatory rheological test was performed, which better mimic 
the in vivo stress conditions in the airways, minimizing the structural changes 
of the glycoprotein. Human bronchial secretions were obtained from CF 
patients at the “Istituto Giannina Gaslini” received as frozen samples at -20°C 
and maintained frozen until use. Before use, samples were softly unfrozen by 
placing them in refrigerator for 12 hours.  
Rheological measurements were performed using an ARES rotational 
rheometer (Rheometrics, Inc.) with a parallel plates geometry (plate diameter 
25 mm, gap of 0.5 mm). Dynamic frequency sweep tests were conducted in 
the frequency range of 0.1–10 rad/s using a strain amplitude of 0.4%, proven 
to be in the linear viscoelasticity range by means of strain sweep preliminary 
measurements. Four parameters were identified dependent on frequency (ω, s
-
1
): η* (complex viscosity), G’ (elastic modulus), G’’ (viscous modulus) and 
tan δ (ratio of G’’ to G’). All samples were tested at 37°C and all experiments 
were carried out under air flux.  
For rheological tests the only gel fraction of the CF mucus was loaded onto the 
plate. The gel phase was separated from the liquid phase either by means of 
centrifugation (10 minutes at 11000 g) or by simply lifting it with a spatula, 
allowing the liquid phase to drip off.  
After the method setting-up, measurements on three mucus specimens (#1, #2, 
#3) coming from three different CF patients were conducted.  
 





Figure 31: Rheological parameters of three mucus samples versus oscillation frequency (ω); 
a) complex viscosity b elastic and viscous modulus) c) Tan δ 
 
As reported in Figure 31a complex viscosity decreased with increasing 
frequency, as for pseudo-plastic fluids, where the macromolecular components 
of the material align themselves in the directions of the applied force, reducing 
their resistance to the flow. The elastic moduli (G’) was always greater than 
the viscous moduli (G’’) (Fig. 31b). Moreover, G’ and G’’ increased with 
frequency. Tan δ values (Fig. 31c) are sensibly less than 1 (G’>G’’), 
indicating an elastic behaviour higher than a viscous one. Considering the 
elastic characteristic of CF mucus and the force applied to the material, this 
test could be qualitatively compared to the stress applied to the mucus in CF 
airways by cilia beats. These preliminary results my explain the retention of 
the mucus in the airway even though the cilia movements: if the material is 




elastic, it will return to its initial shape and size when these forces are not 
exerted any more. 
On the basis of the previous considerations regarding the role of HCO3
¯
 in the 
physiological expansion of mucin, rheological studies were repeated on 1 ml 
of untreated mucus (W, added with 100 µl of water) and on 1 ml of mucus 
obtained from the same patient after the same specimen collection and treated 
in vitro with 100 µl of NaHCO3 (CARB, final concentration in the mucus 
~100mM),. Samples were introduced in an incubator shaker at 37°C for 30 




Figure 32: Rheological parameters of in vitro treated (full symbols) and untreated (empty 
symbols) mucus samples versus oscillation frequency (ω); a) complex viscosity b) elastic and 
viscous modulus c) Tan δ.  
 
The preliminary results showed that the addition of sodium bicarbonate to the 
mucus sample caused a reduction in complex viscosity (Fig. 32a) with a 
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downward shift of both the elastic (rhombi) and viscous moduli (squares), The 
ratio of G’’ to G’ remains unchanged, as indicating by tan δ profiles almost 
overlapped (Fig. 32c). These results although encouraging need to be 
confirmed by further studies because of the paucity of the biological sample 
which prevents to perform all the required experiments. 
 
2B 2.3 Permeation of ketoprofen lysine salt/leu from DPIs through CF 
native mucus and effect of NaHCO3 on drug permeation 
 
Permeation experiments were conducted on five mucus specimens (#1, #2, #3, 
#4, #5), obtained from different CF patients or different expectoration and 
using the Franz cells in a modified configuration interposing the mucus 
between the nitrocellulose membrane and the drug formulation (§4B 5). 
As expected, the mucus layer slowed down drug dissolution and permeation 
compared to buffer permeability, acting as a physical barrier (Fig. 33). 
 
Figure 33: Mucus permeation profiles of ketoprofen lysinate (squares) in comparison with 
drug permeation profile without mucus (circles) 
 
Afterwards, in order to evaluate the fluidizing effect of NaHCO3 on the mucus 
permeation of Klys from the DPI, different experiments were performed with 




and without the mucus layer. To rule out that NaHCO3 effect on mucus was 
due to an osmotic effect, we decided to evaluate also the effect of NaCl 
solution isosmotic with NaHCO3. Thus, it has been necessary to evaluate, 
firstly, the influence of water, NaHCO3 and NaCl solutions and their 
respective pH on dissolution/permeation processes of Klys before studying the 
permeation through CF mucus.  
To this purpose three experiments were performed dusting the powder onto the 
nitrocellulose membrane and adding 50 µl of each solution in the donor 
compartment. Figure 34 showed no significant difference in drug dissolution 
between the experiments carried out with water or with the salt solutions , 
indicating no salt effect on drug dissolution.  
 
Figure 34: Permeation profiles of Klys obtained by adding 50 µl of H2O (full squares), 
NaHCO3 (empty squares) and NaCl (full triangles) in the donor compartment. 
 
Moreover, permeation studies were repeated across the CF mucus treated in 
vitro with 50 µl of NaHCO3 0.5 M before starting the experiments.  
The results in Figure 35 (#1-3) showed higher Klys permeation across CF 
mucus treated with NaHCO3 compare to the untreated one, confirming the 
effect of NaHCO3 in the reduction of mucus viscosity. On the contrary, no 
differences in drug permeation between the treated and untreated mucus were 
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observed for the sample #4. Probably, NaHCO3 fluidizing effect is more 
evident when the mucus is more tenacious.  
 
 
Figure 35: Permeation profiles of Klys through untreated (full squares) and treated (empty 
squares) mucus specimens (#1, #2, #3, #4). 
 
Furthermore, to be sure that NaHCO3 effect on mucus was not due to an 
osmotic effect, one more permeation test was performed treating the mucus 
with 50 µl NaCl solution isosmotic with NaHCO3.  
The results reported in Figure 36 showed that the permeation profiles obtained 
through the mucus treated with NaCl and the untreated mucus are completely 
overlapped confirming that NaHCO3 acts reducing mucus viscosity. 





Figure 36: Permeation profiles of Klys through untreated mucus (full squares), mucus treated 
with NaHCO3 (empty squares) and mucus treated with NaCl (empty circles). 
 
3B 2.3 Conclusions  
 
The preliminary but interesting results seem to confirm the role of NaHCO3 in 
the swelling of the mucus. This weak base appears to act decreasing high 
viscosity of the CF bronchial secretion and, potentially, resulting in a better 
mucus clearance and in a barrier less difficult to overcame by inhaled drugs.  
The valuable information obtained from these studies could suggest a possible 
use of NaHCO3 as a therapeutic agent in the management of Cystic Fibrosis 
and, moreover, could be exploited to improve and develop a mucus model 
with chemical and rheological properties comparable with the CF mucus, 
allowing to perform all the required experiments. 
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The final part of the project was performed at the Woolcock Institute of 
Medical Research in Sydney, under the supervision of Professors Daniela 
Traini and Paul M. Young. The research was aimed to study permeation 
processes of several antibiotics across Calu-3 cell line to obtain key 
information for the future formulation of inhaled products. 
 
3C 1 Background, rationale and aim 
 
Within the past few decades, the lung has received increasing attention as an 
effective pathway of targeted drug delivery for the treatment of chronic 
respiratory diseases and as an alternative route of systemic drug 
administration. Respiratory diseases such as tuberculosis, bronchiectasis, 
pneumonia, cystic fibrosis and chronic obstructive pulmonary disease benefit 
from direct administration of drugs to the lung in form of micronized droplets 
or solid microparticles. Indeed for some of these pathologies, inhaled 
antibiotic therapy has been developed to deliver the drugs directly to the site of 
action, reducing the dosing requirements, systemic toxicity and side effects 
(Geller 2009, Traini et al. 2009, Haghi et al. 2014). During the development of 
inhaled formulations it is crucial to understand the fate of the drug candidates 
after lung deposition, by considering the solubility of the drugs that could 
affect bioavailability. The Biopharmaceutics Classification System (BCS) 
established by Amidon and co-workers (Amidon et al. 1995), allows 
predicting the in vivo pharmacokinetics of the drugs but it is limited to the 
gastrointestinal absorption. Pulmonary administration requires an ad hoc 
study, taking into account the specific biology of the lung (metabolism, 
clearance, mucus and surfactant), as well as the characteristics of the 
formulation (Amidon et al. 1995, Eixarch et al. 2010, Cho et al. 2012).  
Several methods have been employed to investigate pulmonary drug 
absorption such as in vitro cell culture methods, isolated lung perfusion 




models and in vivo pharmacokinetic analyses (Mobley et al. 2001). Among 
these, in vitro cell cultures may be used as primarily screening tools to study 
the mechanisms involved in the absorption, metabolism and retention time of 
the drug in the airway epithelium (Borchardt 1995). A range of in vitro cell 
culture models of the respiratory epithelia have been employed for the 
screening of drugs candidate and moreover to study the pathological processes 
involved in lung diseases (Haghi et al. 2014). 
Several studies have shown that Calu-3, an adenocarcinoma cell line derived 
from human bronchial epithelium, forms tight monolayers in vitro, produces 
secretory components and expresses several efflux and influx transporters 
(Mathia et al. 2002, Florea et al. 2003, Brillault et al. 2009), suggesting the 
usefulness of this cell line as an in vitro model to study pulmonary absorption. 
The objective of this study was to investigate the correlation between 
physicochemical properties of different antibiotics, such as molecular weight, 
solubility, LogP and calculated permeability and their transport across Calu-3 
cell line. The valuable information obtained from these studies, such as the 
rate of antibiotics transported across the epithelial cells and the impact of 
antibiotics physicochemical properties on their transport across the respiratory 
epithelia would be useful for the future formulation of inhaled antibiotics. 
 
3C 2 Calu-3 viability 
 
Firstly, the dose response cytotoxicity profile of antibiotics on Calu-3 cells 
was established. Calu-3 cell cultures were exposed to a range of antibiotics 
concentrations (from a minimum of 0.1 nM to a maximum of 250,000 nM) 
over a 72 h treatment period. Cells viability was calculated with reference to 
the untreated cells, where average absorbance was normalised to 100% 
viability. The viability results (Fig. 37), demonstrated that Calu-3 cells could 
tolerate different concentrations of the antibiotics used in the transport 
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experiments. With regards to the CPF toxicity, data have been previously 
reported in a study by Ong et al., demonstrating that this antibiotic is not toxic 











Figure 37: The effect of different concentrations of AZT, RFP, TBM (a) and DXC, MXF, 
CPF (b) on Calu-3 cell viability after 72 h drug treatment (n = 3, mean ± StDev). 
 
3C 3 Calu-3 transport studies 
 
The transport across Calu-3 cells was measured in both apical to basolateral 
(A-B) and basolateral to apical (B-A) directions as described in the 
experimental procedures (§4C 4). 
For each antibiotic, the donor concentrations were selected based on the 
results obtained from cell viability, taking into account the solubility limit of 
each drug and the limit of detection by HPLC. The following are the 
concentrations of each antibiotic in the donor compartment: 10 and 20 µM for 
CPF, RFP and MXF, 20 and 40 µM for DXC, 100 µM for AZT and TBM, 
respectively. 
Since the donor concentration (C0) of the antibiotics were different, to 
facilitate comparison in terms of the amount transported and retained in the 
cells, the values were plotted as percentages. The percentage of antibiotics 




transported after 180 minutes in the absorptive (A-B) and secretory directions 










Figure 38: Percentage of CPF, RFP, MXF, DXC, AZT, TBM transported from A-B (a) and 
B-A (b) direction across Calu-3 cells after 180 minutes (n = 3, mean ± StDev). 
 
Apical to basolateral transport of CPF was assayed at 10 and 20 µM. Results 
showed that approximately 81.00 ± 24.74 % of 10 µM CPF and only 48.65 ± 
15.70 % of the 20 µM CPF was transported across Calu-3 cells. This finding 
indicates that the transport of CPF was independent of the initial concentration 
and was not transported exclusively through the paracellular route, indicating 
that influx transporters could be involved in the transport of CPF. B-A 
transport showed that only a small percentage of CPF (2.01 ± 1.13 % at 10 µM 
and 0.80 ± 0.14 % at 20 µM) was transported in the secretory direction. These 
results are in good agreement with findings from Ong et al. where it was 
shown that when specific active transporter inhibitors are present, the 
permeability of CPF in both A-B and B-A directions was decreased (Ong et al. 
2013). 
Figure 38a showed that 53.70 ± 20.50 % of 10 µM RFP and only 29.40 ± 8.90 
% of 20 µM RFP was transported in the absorptive direction. These results 
suggested that active transporters can play a role in RFP absorption. Currently, 
there are only few studies on the transport mechanisms for rifampicin in 
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organs such as intestine and lungs. Tewes et al. and Mariappan et al. found 
that RFP permeation across Calu-3 cells and intestinal segments is driven by a 
saturable mechanism (Mariappan et al. 2004, Tewes et al. 2008). Hence, as the 
drug concentration rises, its transport increases up to the point where all the 
transport carriers involved become saturated.  
MXF absorption and secretory transport experiments revealed that the 
percentage of MXF transported was low both in A-B direction (11.80 ± 1.40 
% for C0 of 10 µM) and in B-A direction (12.60 ± 1.55 % for C0 of 20 µM and 
8.50 ± 0.56 % for C0 of 10 µM and 9.43 ± 0.38 % for C0 of 20 µM). Moreover 
no significant difference (P>0.05) in the percentage of antibiotic transported 
was found between the two different concentrations studied, indicating a 
possible passive or paracellular absorption of the antibiotic depending on the 
concentration gradient of the drug in the donor and receiver chambers. These 
results are in agreement with the study by Brillault et al., that reported MXF to 
be a substrate of P-glycoprotein, a well-known membrane efflux transporter 
overexpressed in the apical and basolateral sides of Calu-3 cells. The presence 
of this efflux transporter prevents the MXF to remain inside the cells (Brillault 
et al. 2009), further confirmed by our results in Figure 39 showing the 
percentage of antibiotics recovered inside the cells.  
Similarly, DXC showed a low absorptive and secretory permeation (12.43 ± 
3.65 % for C0 of 20 µM and 7.60 ± 2.60 % for C0 of 40 µM in A-B direction 
and 3.44 ± 0.53 % for C0 of 20 µM and 2.75 ± 0.48 % for C0 of 40 µM in B-A 
direction) probably due to efflux pumps. Moreover, as shown in the Figure 39, 
the percentages of MXF and DXC recovered inside the cells were less than 









Figure 39: Percentage of CPF, RFP, MXF, DXC, AZT, TBM recovered inside the cells after 
180 minutes (n = 3, mean ± StDev). 
 
As reported in Figure 38a AZT did not show A-B transport. The analysis of 
epithelial cells drug content revealed that after 3 hours only a small percentage 
of drug (3.16 ± 0.03 % of 100 µM) was found inside the cells (Fig. 39), and 
90.00 ± 0.60 % of AZT 100 µM was found remaining on the cells. Small 
percentage of AZT (1.57 ± 0.02 % of 100 µM) was transported in B-A 
direction. These results were in agreement with a study by Pachot et al., in 
which the transport of different macrolides was examined across Caco-2 cell 
monolayers and demonstrated the involvement of P-glycoprotein as efflux 
pump in the both absorptive and secretory directions (Pachot et al. 2003).  
Finally, TBM was assayed at different concentrations (ranging from 20 to 100 
µM) but it was only detected in the basolateral compartment (A-B direction), 
when 100 µM initial concentration was used, showing TBM to have low 
permeability. Further studies are required to investigate whether the observed 
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3C 4 Effect of the molecular weight (MW) and logP on the Papp 
 
The epithelial permeability of these antibiotics was calculated as reported in 
the experimental procedures (§4C 5) and investigated in relation to their 
physicochemical characteristics, presented in Table 9. 
 










CPF sps* 1.32 367.84 
MXF s* 0.01 437.89 
RFP vss* 3.72 822.94 
DXC s* -4.17 480.89 
AZT sps* 4.02 785.02 
TBM s* -7.32 467.51 
*Soluble (s), sparingly soluble (sps), very slightly soluble (vss). 
 
Transport of the antibiotics across Calu-3 was calculated as the Papp, cm/s (§ 
4C 5). Calculation of Papp for AZT (C0 20 µM) was not possible in the 
absorptive direction, since no drug was detected in the aliquot sampled from 
the basolateral compartment. To confirm that this antibiotic did not 
permeate/transport through the Calu-3 monolayer, the experiment was 
repeated using higher concentration of AZT (ranging from 20 up to 100 µM) 
and sampling only after 180 min; however, even in this case, no drug was 
detected in the receiver compartment.  
With regard to TBM, different concentrations (ranging from 20 to 100 µM) 
were tested, however, only at 100 µM and following sampling after 180 
minutes, 32.60 ± 3.03 % of initial TBM concentration, was detected in the 




basolateral compartment; consequently, even in this case, the lack of enough 
drug concentration points transported over time prevented the calculation Papp. 
In Figure 40a, the Papp values of the different antibiotics transported from 
apical to basolateral direction (C0 20 µM) are plotted as a function of their 
molecular weights. The Papp of RFP (6.40 × 10
-4
 ± 1.06 × 10
-4
 cm/s) was the 
highest in spite of its high molecular weight. CPF (3.50 × 10
-4
 ± 1.53 × 10
-4
 
cm/s), DXC (2.02 × 10
-4
 ± 2.82 × 10
-5
 cm/s) and MXF (1.59 × 10
-4
 ± 1.46 × 
10
-5
 cm/s), both with low and similar molecular weights, showed different 
values of permeability. These findings indicate that antibiotics transport is 












Figure 40. Apparent permeability (Papp) vs. Molecular weight (MW) (a), and LogP (b) from 
the apical to basolateral across Calu-3 (n=3, mean± StDev). 
 
The relationship between the Papp and the partition coefficient (LogP) of the 
antibiotics in this study is shown in Figure 40b. Generally, the Papp (A-B 
direction) increased with an increase of LogP. This finding is in agreement 
with previous studies where drug lipophilicity has shown to increase the 
transport across the epithelium (Bur et al. 2010). Hence, the highest Papp of 
RFP and CPF are in agreement with the higher LogP values, compared to 
MXF and DXC the most hydrophilic of the investigated antibiotics, 
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accordingly to their lowest Papp values. Moreover, the Papp of RFP, a lipophilic 
drug, led to the hypothesis that passive transport mechanisms could occur in 
addition to the active and saturable transport, as previously discussed. 
Basolateral to apical studies (Fig. 41a) showed that RFP (3.58 × 10
-4
 ± 1.27 × 
10
-4
 cm/s) had the highest Papp value, followed by MXF (2.76 × 10
-4
 ± 1.02 × 
10
-5
 cm/s), DXC (1.31 × 10
-4
 ± 2.50 × 10
-5
 cm/s) and CPF (1.99 × 10
-5
 ± 3.32 
× 10
-6
 cm/s), respectively, indicating no relationship between the Papp and the 
molecular weight of the antibiotics. Furthermore, for most antibiotics in this 
study (DXC, MXF and RFP), Papp increased with an increase of LogP, except 
for ciprofloxacin (average LogP of 1.32) that showed the lowest permeability 
(1.99 × 10
-5
 ± 3.32 × 10
-6












Figure 41. Apparent permeability (Papp) vs. Molecular weight (MW) (a), and LogP (b), from 
the basolateral to apical direction across Calu-3 (n=3, mean± StDev). 
 
On the basis of these results, generally all antibiotics studied (except for MXF) 
showed lower permeabilities in the secretory direction compared with the 
absorptive direction. These findings suggest that the inhalation route would be 
favourable for delivering these antibiotics for the treatment of respiratory 
diseases where infection is present, compared with the present oral or 




intravenous administration that requires high doses of antibiotic to ensure its 
sufficient concentration in the lungs (Ong et al. 2013).  
 
3C 5 Conclusions 
 
In this study the in vitro relationship between physicochemical properties of 
antibiotics for inhalation therapies and their Papp values across human 
bronchial epithelial cell monolayer was investigated. Inverse relationship 
between MW of the antibiotics and permeability was shown both in the 
absorptive and secretory directions. A direct relationship was shown between 
antibiotics permeability and LogP in apical to basolateral transport, while the 
opposite was found for the basolateral to apical.  
These results provide information critically important for the future 
formulation of antibiotics for pulmonary delivery, for both local and systemic 
applications. 
 











































































SECTION A (Parts 1 and 2) 
DESIGN AND DEVELOPMENT OF DPIs CONTAINING 
KETOPROFEN LYSINE SALT TO TREAT INTRINSIC 
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4A 1 Chemicals 
 
Ketoprofen and ketoprofen lysine salt were kindly donated by Dompè spa 
(L’Aquila, Italy); L-leucine, was supplied by Sigma Aldrich (Milan, Italy). 
Isopropyl alcohol (for analysis, USP grade) was purchased from Carlo Erba 
Reagents (Milan, Italy). Other solvents and chemicals were of analytical 
grade. Size 3 gelatine capsules were purchased from Dermolife (Trento, Italy). 
The device used for aerodynamic tests was the monodose DPI model 7 kindly 
donated by Plastiape SpA (Milan, Italy). All the cell culture reagents were 
purchased from Lonza (Milan, Italy). 
 
4A 2 Powders preparation via Mini Spray Drying  
 
Micronized particles, containing ketoprofen or ketoprofen in its lysine salt 
form, were prepared by spray drying the drug alone or with leucine (85:15 
w/w, respectively) as dispersibility enhancer from water or water/isopropyl 
alcohol 7/3 v/v mixtures. Drug alone or with leucine was solubilized in water, 
then the organic solvent was added under continuous magnetic stirring. The 
total powder concentration reached 5% w/v in all batches.  
The liquid feeds containing ketoprofen (pH=3.3) were neutralized with few 
drops of a 1 M sodium hydroxide solution. All the solutions were dried using a 
Buchi mini spray dryer B-191 (Fig. 42) (Buchi Laboratoriums-Tecnik, Flawil, 
Switzerland) under the following operative conditions: inlet temperature 110 
°C, outlet temperature 72-75°C, drying air flow 500 L/min, aspiration rate 
100%, air pressure 6 atmospheres, feed rate 5 ml/min, nozzle 0.5 mm, set in 






Figure 42. BÜCHI B-191 Mini Spray Dryer. 
 
Each preparation was carried out in triplicate and all the spray-dried powders 
were collected and stored under vacuum for 48 h at room temperature. 
Production yields were expressed as weight percentage of the final product 
over the total amount of sprayed material. 
 
4A. 1.3 Powders preparation via Nano Spray Drying  
 
Micronized particles were prepared using BÜCHI B-90 Nano Spray Buchi 
(Fig. 43) (Laboratoriums-Tecnik, Flawil, Switzerland) from different hydro-
alcoholic solutions (IPA from 0 to 30% v/v) containing ketoprofen in its 
lysinate salt form and leucine as dispersibility enhancer in different ratios 
(from 5 to 15% w/w) with a total solid concentration ranging from 1 to 7% 
w/v. Besides solutions compositions, the operating conditions of nano spray 
drier were tuned in order to study their effect on powder technological 
properties.  
 




Figure 43: BÜCHI B-90 Nano Spray 
 
In details, inlet temperature ranged between 60 and 110°C, while air flow rate 
(100 L/min), feed rate (1.5 ml/min), and relative spray rate (100%) were kept 
constant. Solution were sprayed alternatively using nozzles with mesh 
diameters of 4.0, 5.5 and 7.0 µm. A nozzle pre-treatment with surfactant 
solutions was also carried out, aiming to reduce the processing time. 
 
4A. 1.4 Powders physico-chemical characterization 
 
4A. 1.4a Ketoprofen lysinate quantification 
 
Ketoprofen lysinate was quantified by UV detection (Evolution 201, Thermo 
Fisher Scientific, Spectral, Ozzano dell'Emilia, Bologna, Italy) at a wavelength 
of 259 nm, using 1cm SUPRASIL® quartz cell (Hellma 100-QS, HELLMA 
Italia srl, Milan, I). The analytic method was validated using standard 





4A. 1.4b Particle size 
 
Particle size of both raw materials and engineered particles was determined 





dispersing system (LS 13 320 Beckman Coulter Inc., FL, USA). The LS 13 
320 uses a 5 mW laser diode with a wavelength of 750 nm and reverse Fourier 
optics incorporated in a fibre optic spatial filter and binocular lens systems. 
The particle size was obtained by a specific software using Mie theory to 
produce an optimal analysis of the light energy distribution. The tornado 
module leads to a dispersion similar to the one achieved when the samples are 
run wet, without using any solvent which can alter powder surface properties 
(Stewart et al. 2009). Samples were charged into a plastic cylinder in order to 
obtain an obscuration value between 4 and 8%.  
Results were expressed as d50 and span, defined as [d(90) − d(10)]/d(50), where 
d(10), d(50) and d(90) indicate diameters at the 10th, 50th and 90th percentiles of 
the particle size distribution, respectively. 
 
4A. 1.4c Particle morphology 
 
Morphology of raw materials and microparticles was examined using a 
scanning electron microscope (SEM) Zeiss EVO MA10 (Carl Zeiss SMT AG, 
München-Hallbergmoos, Germany) operating at 14 kV. 
 
4A. 1.4d Differential scanning calorimetry analysis 
 
Differential scanning calorimetry (DSC) was performed with an Indium-
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Accurately weighed samples (3-5 mg) (MTS Mettler Toledo microbalance, 
OH, USA) were placed in a 40 μL aluminium pan, which was sealed, pierced 
and heated up to 350°C at a heating rate of 20°C/min. 
 
4A. 1.4e Bulk and tapped density 
 
Bulk density of the spray-dried powders was measured as described elsewhere 
(Sansone et al. 2009). Briefly, powders were loaded into a bottom-sealed 1 ml 
plastic syringe (Terumo Europe, Leuven, Belgium) capped with laboratory 
film (Parafilm® “M”, Pechiney Plastic Packaging, Chicago, IL, USA) and 
tapped on a hard bench until no change in the volume of the powder was 
observed. The bulk and tapped densities were calculated from the net weight 
of the plastic syringe content divided by the powder volume in the syringe 
before and after tapping, respectively. Experiments were performed in 
triplicate. 
 
4A. 1.5 Aerodynamic behavior evaluation 
 
Powders aerodynamic properties were assessed by Andersen cascade impactor 
(apparatus D, Eur. Ph. 6.0, ACI, Westech Instrument Services Ltd., 
Bedfordshire, UK) and the effective cut-off diameters of the ACI (Fig. 45) 
were: Stage −1, 8.6 μm; Stage −0, 6.5 μm; Stage 1, 4.4 μm; Stage 2, 3.2 μm; 
Stage 3, 2.0 μm; Stage 4, 1.1 μm; Stage 5, 0.54 μm; Stage 6, 0.25 μm modified 








Figure 45: Andersen cascade impactor. 
 
The device used to aerosolize the powders was the monodose® (Plastiape, 








The capsule is horizontally inserted into the pulverization chamber and pierced 
by two needles at the bottom and at upper side: the inhaled air creates a 
turbulence that shakes and twists the capsule, facilitating its empty. In order to 
minimize particle bounce, metal impaction plates were dipped into an n-
hexane solution of SPAN 80 (0.1% w/v) and the solvent was allowed to 
evaporate, leaving a thin film of SPAN 80 on the plate surface. The ACI was 
assembled placing a filter paper on the filter stage and the monodose DPI was 
fitted into a rubber mouth piece attached to the metal throat. Four hard gelatine 
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capsules (size 3) were filled manually with 40 ± 0.5 mg of sample. Each 
capsule was introduced into the monodose DPI and pierced. The vacuum 
pump was actuated for 4 s. The powder deposited into the different stages was 
recovered by plunging each plate and the stage below into distilled water (5-
500 ml depending on the stage number). Drug content was assessed by UV 
measurements. The emitted dose (ED) was gravimetrically determined and 
expressed as percentage of powder exiting the device versus the amount of 
powder introduced into the capsule. The cumulative mass of powder with a 
diameter lower than the stated size of each stage was calculated and plotted as 
a percentage of recovered powder vs cut-off diameter. The mass median 
aerodynamic diameter of the particles was extrapolated from the graph, 
according to the Eur. Ph. 6.0. From the same plot, the fine particle dose (FPD), 
i.e. the mass of drug with a particle size less than 5 μm, and the fine particle 
fraction (FPF), i.e. the fraction of drug emitted from the device with a particle 
size less than 5 μm, were determined. In vitro deposition experiments were 
performed on three batches with three replicates each.  
 
4A. 1.6 Biological activity 
 
4A. 1.6a Cell lines and culture conditions 
 
CuFi1 cell line, derived from human bronchial epithelium of a CF (CuFi1, 
CFTR ΔF508/ΔF508 mutant genotype) were purchased from American Type 
Culture Collection (ATCC, Manassas, VA, USA). CuFi1 cells were grown in 
human placental collagen type VI coated flasks (Sigma–Aldrich, Milan, Italy) 
in bronchial epithelial basal medium BEGM (Clonetic Lonza Walkersville. 
Inc) supplemented with BPE, hydrocortisone, hEGF, epinephrine, insulin, 





penicillin/streptomycin (50 mg/ml). Cells were incubated at 37°C in a 
humidified atmosphere containing 5% CO2. 
For in vitro biological studies, stock solutions of powders were prepared in 
sterile water, and then opportunely diluted with BEBM and immediately 
administered to the cells. 
 
4A. 1.6b Proliferation assay 
 
Cell growth was assessed by using a colorimetric bromodeoxyuridine (BrdU) 
cell proliferation ELISA kit (Roche Diagnostics, Milan, Italy). Briefly, 5 × 10
3
 
cells were seeded into each coated well of a 96-well plate and left to adhere to 
the plate. The cells were then treated with increasing concentrations (from 0.1 
to 1000 µM, expressed as ketoprofen content) of raw ketoprofen, raw 
ketoprofen lysine salt, Klys-1a and Klys-2a for 48 h. BrdU was added for the 
final 16 h (10 µM final concentration). At the end of the whole cell culture 
period, the medium was removed and the ELISA BrdU immunoassay was 
performed as described by the manufacturer. The colorimetric reaction was 
stopped by adding H2SO4, and the absorbance at 450 nm was measured using 
a microplate reader (Bio-Rad Laboratories, Milan, Italy). 
 
4A. 1.7 Statistical analysis 
 
Measurements were performed in triplicate, unless otherwise stated. Values 
were expressed as means of at least three experiments with three replicates 
each ± SD. Statistical differences between the treatments and the control were 
evaluated by the Student's t-test A (P values less than 0.05 were considered 
statistically significant). 
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4B 1 Chemicals 
 
Ketoprofen lysine salt was kindly donated by Dompè spa (L’Aquila, Italy); 
Gentamicin sulphate (G), L-leucine (leu), o-phthalaldehyde, Isopropanol (for 
analysis, USP grade) and sodium hydroxide anhydrous pellets used for the G 
quantification were supplied by Sigma Aldrich (Milan, Italy). Other solvents 
and chemicals were of analytical grade. Deoxyribonucleic acid, mucin from 
porcine stomach, diethylenetriaminepentaacetic acid (DTPA), RPMI 1640 
Amino Acids Solution, egg yolk emulsion, sodium chloride and potassium 
chloride used for artificial mucus preparation were supplied by Sigma Aldrich 
(Milan, Italy) and high viscosity hydroxyethylcellulose by A.C.E.F. SpA 
(Piacenza, Italy). 
 
4B 2 CF artificial mucus 
 
Basic CF artificial mucus (AM-) was firstly prepared as previously reported 
(Sriramulu et al. 2005). Briefly, 4 g of deoxyribonucleic acid (DNA), 5 g of 
mucin, 5.9 mg of diethylenetriaminepentaacetic acid (DTPA), 20.0 ml of 
RPMI 1640 Amino Acids Solution, 5 ml of egg yolk emulsion, 5.0 g NaCl and 
2.2 g of KCl were mixed together in 1l of distilled water (final volume). The 
pH of the resulting solution was adjusted to 7.0 ± 0.1 by a NaOH solution. 
However, AM
- 
was too fluid (viscosity not detected) and passed through the 
membrane pores during 60 min, preventing the permeation study. 
Consequently, two more different models, AM1 and AM1.5, were prepared, 
adding 1% and 1.5% w/v of HEC (hydroxyethylcellulose), respectively, as an 
inert thickening agent to the previous formula. These solutions were allowed 
to equilibrate at 25°C for 12h before any analysis or use, and characterized for 






4B 3 Viscosity measurement of artificial mucus 
 
Viscosity of AM1 and AM1.5, was determined by means of a rotational 
viscometer (Smart Series, Fungilab SA, Barcelona, Spain), based on the 
measurements of the torque of a rotating spindle in a sample at a specified 
velocity. Samples were inserted in a 150 ml glass becker. Viscosity tests were 
conducted using the R2 spindle at different velocity (100-60-50-30-20-10 
rpm). Data were reported as Pa×S related to the rotor velocity (ω); the 
resulting viscosity values were always between 15% and 100% of the torque 
range, as requested. 
 
4B 4 Rheological measurement of CF mucus patients 
 
Rheological measurements were performed using an ARES rotational 
rheometer (Rheometrics, Inc.) with a parallel plates geometry (plate diameter 
25 mm, gap of 0.5 mm). Dynamic frequency sweep tests were conducted in 
the frequency range of 0.1–10 rad/s using a strain amplitude of 0.4%, proven 
to be in the linear viscoelasticity range (LVR) by means of strain sweep 
preliminary measurements. Four parameters were identified dependent on 
frequency (ω, s
-1
): η* (complex viscosity), G’ (elastic modulus), G’’ (viscous 
modulus) and tan δ (ratio of G’’ to G’). All samples were tested at 37°C and 
all experiments were carried out under air flux.  
 
4B 5 In vitro permeation study 
 
Permeation assays were performed by means of Franz-type vertical diffusion 
cells (Hanson research corporation, CA, USA).  




Figure: 47. Franz cell used in permeation studies: a) standard configuration with one dosage 
wafer housing the drug formulation; b) modified configuration with three dosage wafers 
housing mucus and drug formulation. 
 
The cell system temperature was kept constant at 37°C throughout the 
experiment by recirculating water from a thermostatically controlled bath. 
Continuous stirring at 170 rpm was provided by Teflon-coated stirring bars 
placed in the receptor compartment. Firstly, permeation experiments were 
conducted with Franz cells in a standard configuration (Fig. 47a), spreading 
the powder directly on the membrane. The receptor compartment was filled 
with 7 mL of a 0.05 M phosphate buffer (pH 7.4) and a nitrocellulose 
membrane (size pores: 0.45µm), previously set with phosphate buffer, was 
applied between the two compartments (permeation area 1.77 cm
2
). About 35 
mg of the selected powder, precisely weighed, were uniformly dusted on the 
membrane surface in the dosage wafer, which was subsequently sealed with 
spring clips and laboratory film (Parafilm
®
). Samples (200 µl) were removed 
at defined time intervals (5, 10, 15, 20, 30, 45, 60 min) inserting the same 
volume of warmed buffer. 100 µl aliquots were analyzed for drug content. The 
amount of the drug permeated per area (Q) for each time interval was 

















VR is the receiver volume; 
Cn is the drug concentration in the receiver at the time n; 
VP is the volume of the removed sample; 
Ci is the drug concentration in the receiver at the time n-1; 
A is the permeation area (cm²). 
 
Permeation data were reported as the quantity of permeated drug per 
permeation area (mg/cm
2
) related to time.  
In a second set of experiments, Franz cells were used in a modified 
configuration (Fig. 47b) (Donnelly et al. 2007): a thin layer (3mm) of artificial 
mucus AM1 or AM1.5 was interposed between the nitrocellulose membrane 
and the drug formulation (about 35 mg of powder exactly weighed). Samples 
(200 µl) were removed from the outer sampling port at defined time intervals 
(30, 45, 60, 90, 120, 150, 180 min) and analyzed.  
 
4B 6 Gentamicin Sulfate quantification 
 
G quantitative determination by HPLC followed the Pharmacopoeia method 
(USP 30) as reported elsewhere (Della Porta et al.). Briefly, 25 mg of G raw 
material was stirred in 25 ml of distilled water until complete dissolution. Five 
ml of IPA and 4 ml of a previously prepared phthalaldehyde solution were 
then added to 10 ml of this solution. The solution was stirred and IPA was 
added to reach a 25 ml volume. Finally, it was heated for 15 min in a water 
bath at 60 °C, cooled at room temperature, filtered through 0.45 µm filters and 
analyzed by HPLC at a wavelength of 330 nm (Chromatopac L-10AD system 
equipped with a Model SPD-10AV UV–vis detector and a Rheodyne Model 
7725 injector loop 20 µl, Shimadzu, Kyoto, Japan). Peak areas were calculated 
with a Shimadzu C-R6A integrator. Phthalaldehyde solution was obtained 
dissolving 1.0 mg of o-phthalaldehyde in 5 ml of methanol and adding 95 ml 
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of 0.4 M boric acid, previously adjusted with 8 N KOH to a pH of 10.4, and 2 
ml of thioglycolic acid. The pH of the resulting solution was adjusted to 10.4 
by a 8 N KOH solution. Calibration curves were worked out and 
proportionality between G concentration and AUC was checked in the range 
of 5-500 μg/ml.  
After adding the phthalaldehyde solution to a sample containing both G and 
leu, the amino acid reacted with phthalaldehyde, giving rise to a chromophore 
absorbing at 330 nm, as observed for G, with no interference with G. 
Calibration curves were worked out for leu, too, and proportionality between 
leu concentration and AUC was tested in the range of 1-20 μg/ml.  
 
4B 7 Ketoprofen lysinate quantification 
 
Ketoprofen lysinate was quantified by UV detection (Evolution 201, Thermo 
Fisher Scientific, Spectral, Ozzano dell'Emilia, Bologna, Italy) at a wavelength 
of 259 nm, using 1cm SUPRASIL® quartz cell (Hellma 100-QS, HELLMA 
Italia srl, Milan, I). The analytic method was validated using standard 
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4C 1 Chemicals 
 
Calu-3 cells were purchased from the American Type Culture Collection 
(ATCC, Rockville, MD, USA). Nonessential amino acids solution, CelLytic 
M Cell Lysis, protease inhibitor cocktail and dimethyl sulfoxide (DMSO), 
were purchased from Sigma-Aldrich (Sydney, Australia). Other cell culture 
reagents including trypsin-EDTA solution (2.5 g/L trypsin, 0.5 g/L EDTA), 
Dulbecco’s modified Eagle’s medium (DMEM, without phenol red and L-
glutamine, including sodium bicarbonate and 15 mM HEPES), Trypan blue 
solution (0.4 % w/v), phosphate buffered saline (PBS), L-glutamine solution 
(200 mM), fetal bovine serum (FBS), and Hanks balanced salt solution 
(HBSS) were obtained from Invitrogen (Gibco, Invitrogen, Sydney, Australia). 
Transwell cell culture inserts (0.33 cm
2
 polyester, 0.4 μm pore size) were 
purchased from Corning Costar (Lowell, MA, USA), and all other sterile 
culture plastic wares were from Sarstedt (Adelaide, Australia). All solvents 
used were of analytical grade and were supplied by Biolab (Victoria, 
Australia). Ciprofloxacin (CPF) HCl, azithromycin (AZT) dihydrate and 
moxifloxacin (MXF) HCl were purchased from Sigma-Aldrich (Sydney, 
Australia), rifampicin (RFP) was purchased from Hangzhou ICH Imp & Exp 
Company Ltd. (Hangzhou, China), doxycycline (DXC) HCl was purchased 
from MP Biomedicals Inc (Ohio, USA) and tobramycin (TBM) was kindly 
gifted from Lisapharma S.P.A (Erba, Italy).  
 
4C 2 Cell culture 
 
The Calu-3 cell line (HTB-55) between passages 35 and 42 were maintained 
in tissue culture flasks of 75 cm
2 
and cultured in pre-warmed DMEM 
supplemented with 10% (v/v) fetal bovine serum, 1% (v/v) nonessential amino 





37°C in 5% CO2 and 95% humidity until confluence was reached. Medium 
was exchanged every 2 to 3 days, and the cells were passaged weekly, 
according to ATCC-recommended guidelines. Calu-3 cells were grown at the 
air interface to allow monolayer differentiation. These conditions have 
previously been established by Haghi et al. (Haghi et al. 2010) and Grainger et 





in the apical compartment of the 24-well Transwell cell culture inserts in 100 
µl medium and 500 µl medium was added to the basolateral chamber. 
Subsequently, the medium in the apical chamber was removed after 24 h and 
was replaced in the basolateral chambers only every 2 to 3 days. The transport 
experiments were performed between days 11 and 14 after the seeding. 
 
4C 3 Viability of Calu-3 cells following exposure to antibiotics 
 
The viability of Calu-3 cells following exposure to different concentrations of 
antibiotics were assessed by colorimetric MTS (3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium) in vitro assay, 
according to the method described by Scalia et al. (Scalia et al. 2013). Briefly, 
5 × 10
4
 cells were seeded per well in a volume of 100 µl into a 96 well plate. 
Cells were incubated overnight at 37°C in 5% CO2 atmosphere.  
Concentrations of the antibiotics assessed were as following: CPF up to 50 
uM, MXF from 8.0 × 10
-4
 to 100 μM, RFP from 1.0 × 10
-4
 to 25 μM, AZT, 
DXC, CPF and TBM from 1.0 to 250 μM. After 24 h, 100 µl of increasing 
concentrations of antibiotics were added to each well. The stock solution of 
each antibiotic was prepared by dissolving the drug in ethanol or DMSO and 
further diluting it with the complete medium to the final ethanol concentration 
of ⩽1%. Untreated and solvent controls were included for each experiment. 
Plates were incubated for 72 h at 37°C in a humidified atmosphere with 5% 
CO2. Cells were then analysed for cell viability. Briefly, 20 μL of CellTiter 
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96® Aqueous assay (MTS reagent) (Promega, USA) was added to each well 
and the plates incubated for 3 h at 37°C in humidified 5% CO2 atmosphere. 
Absorbance was measured at 492 nm using a plate reader (Spectramax M2 and 
Soft Max pro 4.8, Molecular Devices, Sunnyvale, CA, USA). The absorbance 
value was directly proportional to cell viability (%). Data were expressed as % 
cell viability [(average absorbance of treated wells/average absorbance of 
control wells) × 100]. The half maximal inhibitory concentration (IC50) values 
were defined as the drug concentration that produces a decrease of 50% in cell 
viability compared to the untreated control. IC50 values were calculated by 
plotting (%) cell viability against the concentrations (ng.ml
−1
) on a logarithmic 
scale. Data was fitted to the Hill equation using the General Fit function of 
KaleidaGraph 4.1 software. Each experiment was performed in triplicate. 
 
4C 4 Calu-3 transport experiments of the antibiotics 
 
The transport across the cells was measured in both apical to basolateral (A-B) 
and basolateral to apical (B-A) directions. Schematic diagram of transport 
experiments is reported in Figure 48. 
 
 
Figure 48: Schematic diagram of transepithelial transport across Calu-3 cells 
 
The selected model antibiotics were dissolved in transport buffer (HBSS). The 
concentration of drug solutions were chosen based on the toxicity of each 





high performance liquid chromatography (HPLC). The volume of antibiotic 
solution in the apical compartment was 150 µl for A-B transport, while the 
receiver compartment was loaded with 350 µl of HBSS. For the B-A transport, 
350 µl of antibiotic solution was added to the basolateral compartment and the 
receiver compartment contained 150 µl of HBSS. 
Aliquot of samples were drawn from the receiver compartments at pre-
determined time points (30, 60, 120, 180 min) and the sample volume was 
replaced with fresh pre-warmed HBSS. 
The cell layer was then harvested for analysis of the drug content inside the 
cells according to the method previously described (Haghi et al. 2010). 
Briefly, the cells were harvested and lysed using CellLytic M Cell Lytis 
buffer, following a centrifugation at 10000 g for 10 min. the supernatant was 
collected for the analysis for the cellular drug content.  
 
4C 5 Sample quantification 
 
Sample concentrations were determined by HPLC. A Shimadzu Prominence 
UFLC system equipped with an SPD-20A UV-Vis detector, LC-20AT solvent 
delivery unit, SIL-20A HT Autosampler (Shimadzu Corporation, Japan) was 
used for the analysis. The column, wavelength and mobile phase composition 
for each antibiotic studied are shown in Table 10. Flow rate was 1.0 ml/min 
and the injection volume was 70 µl for all samples tested. The apparent 











  (2) 
 
Where dQ/dt is the linear transport rate of the drug, A is the surface area of the 
cell monolayer and C0 is the initial concentration in the donor compartment. 
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Table 10. HPLC analysis conditions of all antibiotics. 
 




Ciprofloxacin HCl  Methanol: 0.1 M phosphate buffer (30:70 v/v) 
pH=3.35  
NovaPak C18 (5 µm, 150 x 3.9 mm) 
275 
Moxifloxacin HCl Acetonitrile: 0.1 M phosphate buffer (25:75 v/v)  
pH=4.6  
XBridge C18 (5 µm, 150 x 4.6 mm) 
307 
Rifampicin Methanol: Water (85:15 v/v) 
XBridge C18 (5 µm, 150 x 4.6 mm) 
254 
Doxycycline HCl Acetonitrile: 0.1 M phosphate buffer (30:70 v/v)  
pH=3.35 




Methanol: 0.03 M phosphate buffer (80:20 v/v)  
pH=9.5 
XBridge C18 column (5 µm, 150 x 4.6 mm) 
210 
Tobramycin Derivatization method according to  
Pharmacopoeia (USP 34) 
365 
 
4C 6 Statistical analysis 
 
Measurements were performed in triplicate, unless differently stated. Values 
expressed as mean of at least three experiments with three replicates each ± 
SD. Statistical differences between the treatments and the controls were 
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LIST OF ABBREVIATIONS 
 
Papp   Apparent permeability 
AA   Amino acid 
ACI   Andersen cascade impactor 
API   Active Pharmaceutical Ingredients  
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